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General Introduction  
 
1. Epidemiology 
Lung cancer is the second most common cancer in men and women, and is the 
leading cause of cancer related death. In industrialized countries the mortality rate 
of lung cancer is higher than the mortality rate of breast, colorectal and prostate 
cancer combined 1. When lung cancer is diagnosed at an early stage patients are 
considered to have the best overall survival rate 2. Unfortunately, only a minority of 
patients is currently diagnosed at a curable stage of disease. The lack of specific 
symptoms at an early stage of the disease, the rapid growth of tumor cells and the 
metastatic behavior of lung tumors are the main reasons for a diagnosis at an 
advanced stage.  
Non-small-cell lung cancer (NSCLC) can be divided into three major histological 
subtypes: squamouscell carcinoma, adenocarcinoma, and large-cell carcinoma 3. 
Eighty-five percent of the lung cancer patients are diagnosed with NSCLC, and 
75% of the patients are diagnosed with an incurable stage IIIB or IV disease 4, 5. 
Fifteen percent of the lung cancer patients have small-cell-lung cancer (SCLC) 
and the 5-year survival for them is even lower than for NSCLC 6. 
Whereas originally smoking is at the root of all types of lung cancer, the incidence 
of lung cancer in never smokers increases 7. Smoking is most strongly linked with 
SCLC and squamous-cell carcinoma 8, 9, although after the introduction of filter 
cigarets an increased incidence of adenocarcinomas was observed 10. This 
resulted in a change in ratio of adenocarcinomas-squamous cell carcinomas 
towards adenocarcinomas 8, 11. In some countries squamous cell carcinoma is still 
the most common histological type of lung cancer in male patients, e.g. France 
(41%) and United Kingdom (40%). In other countries adenocarcinoma is the most 
common type e.g. USA and Canada 12. In patients without a smoking history 
adenocarcinoma is most common 13-16.  
Despite new insights and improved medical treatments, lung cancer remains the 
type of cancer with the highest mortality. Additional studies are needed to improve 
detection of lung cancer in an early (pre)malignant stage to improve survival. 
Improved pretreatment staging of lung cancer is necessary to prevent under- or 
over treatment.  Furthermore a better understanding of tumor behavior improves 
treatment modalities.  
In this introduction the histological subtypes of lung cancer, the microenvironment 
of lung cancer and systemic treatment modalities are described. Furthermore 
several imaging techniques to analyze the microenvironment of lung cancer tissue 
are discussed. 
 
2. Histological subtype classification. 
2.1. Introduction 
Historically, the distinction between NSCLC and SCLC determined the choice of 
treatment and prognosis 17, 18. Since the development of new treatment options it 
has become more important to distinguish the histological subtypes of NSCLC, 
such as adeno-, squamous cell- and undifferentiated carcinoma 19-24.  
According to the World Health Organization (WHO) classification, the diagnosis of 
lung cancer is based on the morphological evaluation of histological sections 3. 
The classification of the histological subtypes of lung cancer is largely based on 
standard hematoxylin and eosin section 3.  
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2.2. Adenocarcinoma 
Morphologically, adenocarcinomas show variable glandular structures. Tumor cells 
may be arranged in gland-like aggregates or papillary structures, have vacuolated 
cytoplasm, and feature nuclei with prominent nucleoli 3. Adenocarcinomas of the 
lung often show differentiation toward type II (Clara cells) 25. Thyroid transcription 
factor 1 (TTF1) plays an important role in production of surfactant 26. This factor is 
expressed in 75% of pulmonary adenocarcinomas 26. Other markers related to 
pulmonary adenocarcinomas are Cytokeratin (CK)7 and CK20 26. Adeno-
carcinomas are mainly located in the peripheral lung parenchyma, but other 
locations are possible such as in central bronchial tissue or they may occur in 
combination with lung fibrosis 3. Approximately 35% of all adenocarcinomas are 
diagnosed as stage IV disease 3.  
 
2.3. Squamous cell carcinoma 
Squamous cell carcinomas are characterized by variable keratinizing tumor cells 
and the presence of intercellular bridges 25.  These tumors are macroscopic grey 
or white and can be large in size and cavitate. Squamous cell carcinoma is 
characterized by a high level expression of keratin genes 26. Especially keratin 
genes 5,6,13,14,16,17 and 19 are prominent among the expression markers 3, 26. 
Also over expression of p53 related gene p63 is characterized for squamous cell 
carcinoma 3. TTF-1 is mainly negative (90%) in squamous cell carcinomas 26. 
Prognosis of squamous cell carcinoma is in general better than 
adenocarcinomas3. It metastasizes less frequently than other lung cancers 27. 
Loco regional recurrence is more common in squamous cell carcinomas than in 
other lung tumors 27. The mortality rate in patients with resected T2aN0M0 
squamous cell carcinomas is better compared to adenocarcinomas with the same 
staging 28.  
 
2.4. Adenosquamous carcinoma 
Adenosquamous carcinoma has components of both adenocarcinoma and 
squamous cell carcinoma with each comprising at least 10% of the tumor 29. The 
frequency of this type of tumor is 0.4-4% of all lung carcinomas 3, 29. Diagnosis of 
this type of cancer is difficult. Squamous cell carcinomas with alveolar or acinar 
structures can easily be mistaken for glandular differentiation. Also easily 
misinterpreted is an adenocarcinoma with squamous metaplasia on the attached 
bronchiolar structures. Adenosquamous carcinoma is more aggressive than the 
regular adenocarcinoma or squamous cell carcinoma 29, 30. Etiology of the tumor is 
still unclear. Some suggest that the two cell components (squamous and adeno) 
arise from the same clone or genetically related cellular clones 31. 
 
2.5. Large cell carcinoma 
Large cell carcinomas are by definition poorly differentiated tumors and account 
for approximately 9% of all lung carcinomas 3. It is a diagnosis of exclusion, made 
after ruling out the presence of a component of squamous cell carcinoma, 
adenocarcinoma or SCLC 3. Whether large cell carcinoma itself is a separate type 
of lung cancer or a poorly differentiated type of squamous cell- or adenocarcinoma 
is unknown. Histological presentation consists of nests with large polygonal cells 
with vesicular nuclei, prominent nucleoli and a moderate amount of cytoplasm 3. 
No specific immunohistochemical markers are present for large cell carcinomas.  
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2.6. Large cell carcinomas with neuroendocrine differentiation 
Large cell carcinomas with neuroendocrine differentiation (LCNEC) account for 
about 3% of all types of lung cancer 32, 33. Microscopically the cells are large with 
abundant cytoplasm. Nucleoli are frequent and prominent, facilitating the 
distinction with SCLC 3. Confirmation of neuroendocrine differentiation can be 
obtained by immunohistochemical markers such as chromogranin, synaptophysin 
and CD56 34. Differentiation of LCNEC from other types of NSCLC is important 
because this type of tumor resembles the biological behavior of a SCLC 34 and is 
associated with a higher recurrence rate 35. 
 
2.7. Small cell lung cancer 
SCLC is an epithelial tumor consisting of small cells with scant cytoplasm, ill-
defined cell borders, finely granular nuclear chromatin, and absent or not clearly 
visible nucleoli 25. The cells are round, oval, and spindle-shape and nuclear 
molding is prominent 25. Necroses and a high mitotic count are typical for SCLC 3. 
Around 60% of the SCLC tumors is positive for CD56 and chromogranin 36. Also 
90% is positive for TTF-1 3, 26. Negative prognostic parameters include extensive 
staging, low performance score, elevated serum LDH, low plasma sodium and 
albumin 37-39. 
Although the precise cell of origin is not known for SCLC, it is likely to be a 
pluripotent bronchial precursor cell that can differentiate into each of the major 
histological subtypes of lung cancer 3. 
SCLC appears as hilar or perihilar masses often with mediastinal 
lymphadenopathy. Superior Vena Cava obstruction is seen in 10% of the patients 
at diagnosis 40.  
Due to widespread dissemination at diagnosis, it was common to divide SCLC in 
limited and extended disease. Limited was defined as restricted to one hemi 
thorax with regional lymph node metastases 41. The included lymph nodes are 
hilar and mediastinal ipsilateral and contralateral as well as ipsilateral and 
contralateral supraclavicular lymph nodes 2. In addition, ipsilateral pleural effusion 
(independent of cytology) was limited disease 2. All patients with sites of disease 
beyond the definition of limited disease, equivalent to stage IV, were defined as 
extended disease 2. Within the 7th edition of the TNM classification of lung tumors, 
it is recommended to use the TNM classification for all SCLC cases 42, 43. 
 
2.8. Carcinoid tumor 
Carcinoid tumors are characterized by neuroendocrine differentiation growth 
patterns 3. Histologically tumor cells have a uniform cytological feature. Carcinoid 
tumors are classified as typical and atypical carcinoids 44. Typical carcinoid is a 
tumor with less than 2 mitosis per 2 mm2 and the absence of necrosis. Atypical 
carcinoid has 2-10 mitosis per 2 mm2 and/or foci of necrosis 44. Although this 
tumor is indolent, it is classified as a malignancy because it can invade and 
metastasize 45. Diagnosis can be confirmed by histology or cytology obtained 
during bronchoscopy, but a large piece of well-preserved tumor is needed to 
differentiate between typical and atypical carcinoid 45. Pulmonary carcinoids are 
derived from neuroendocrine cells which exist in normal airways. These 
neuroendocrine cells are numerous in fetal lungs and become less common in 
adult lungs. Histopathologically, the most common carcinoid patterns are organic 
and trabecular, in which the tumor cells are respectively arranged in nests or 
cords3.  
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2.9. Conclusion  
Although awareness of different histological subtypes in lung cancer existed, the 
distinction was limited to NSCLC and SCLC. This was due to limitation of 
treatment options. Nowadays differences in tumor location, growth rate, and 
metastasis behavior have been observed within the group of NSCLC. The 
consequence is more recognition of certain treatment modalities, and changes in 
prognosis between the histological subtypes. Microscopical differences between 
the histological subtypes are a major challenge for pathologists. The positive 
predictive value for SCLC is high (94%) 46 but this does not account for large cell 
carcinomas (23%). This is probably because the specific features for 
adenocarcinomas and squamous cell carcinomas are missing 46. Sample size is 
an important factor in achieving the correct diagnosis 46. The increased numbers of 
cytology specimen obtained by endoscopic ultrasound fine needle aspiration 
(EUS-FNA) and endobronchial ultrasound (EBUS) will make it more difficult for the 
pathologist.  
 
3. Metabolic microenvironment of lung cancer 
3.1. Introduction  
A solid tumor must be seen as a poorly organized “organoid” 47. Its function is 
maintained by interaction between neoplastic and host cells. This interaction 
constitutes the tumor metabolic   microenvironment 47. The metabolic 
microenvironment defined by Vaupel et al includes tumor perfusion, tumor 
oxygenation, pH distribution and metabolic bioenergetic status 48. The concept of 
tumor metabolic microenvironment is beyond the scope of this introduction. The 
introduction will be restricted to the three main features of metabolic 
microenvironment: hypoxia, angiogenesis and glycolysis.  
 
3.2. Hypoxia 
Hypoxia is defined as a state of reduced O2 availability or decreased O2 partial 
pressure below critical thresholds, restricting or even abolishing the function of 
organs, tissues, or cells 49. It has been reported as a key factor in the 
aggressiveness of solid cancer tumors 49-51. Evidence exists that hypoxia is an 
early step in carcinogenesis 52-54. 
Tumor hypoxia is the result of imbalance between oxygen consumption and 
oxygen supply 55. Several mechanisms are responsible for hypoxia 56. First, 
hypoxia can be caused by inadequate blood flow in the tumor tissue 56. Inadequate 
vascular network and impaired blood vessels result in an absence of flow 
regulation or stasis. Second, hypoxia can be caused by increased diffusion 
distance 48, 56. By tumor expansion without increasing microvessel network the 
distance between the oxygen providing vessel and the cell becomes too large. 
Third, anemia can cause a reduced oxygen supply to tumors 56, 57.  
Hypoxia can induce apoptotic cell death in normal and malignant cells 58, but 
malignant cells are able to adapt to low hypoxia levels by changing their gene 
expression pattern. Hypoxia-inducible factor 1 (HIF1) is one of the best known and 
studied transcription factors for hypoxia 49. This transcription factor consists of a 
HIF-1a and HIF-1b subunit. HIF-1a reflects HIF1 activity due to rapid expression in 
hypoxic conditions 59, HIF 1b is hypoxia independent 60. In the absence of oxygen 
the prolyl hydroxylase domains that use oxygen in the hydroxylation reaction are 
inactive 60.  HIF “escapes” hydroxylation and reaches a higher steady state level. 
HIF1a when stabilized rapidly translocates to the nucleus and binds its partner 
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HIF1b 60. Together they bind to target genes through a recognition DNA sequence, 
5′-RCGTG-3′, referred to as a hypoxia response element 60. So, in the absence of 
oxygen where the prolyl hydroxylase domain is inactive, HIF modulates the 
expression of genes involved in functions such as metabolism, 
invasion/metastasis and apoptosis/survival 60. HIF1a expression also induces the 
transcription of vascular endothelial growth factor-A (VEGF-A) genes by binding 
HIF to the VEGF-A-promoter 60. The product of this gene stimulates 
neoangiogenesis and re-establishes oxygen and nutritional homeostasis 61. In 
several studies HIF1-a expression is associated with poor prognosis in early stage 
of lung cancer 59, 62, 63. Tumor hypoxia has a heterogeneous distribution and has 
been related with invasive growth and metastasis 64, 65. HIF1a is able to induce 
expression of certain epithelial-mesenchymal transition regulators 62. Epithelial-
mesenchymal transition is considered as one of the major molecule mechanisms 
inducing metastasis 62, 66. Due to diminished oxygen radicals, tumor hypoxia is 
related to increasing resistance to radiation therapy 67. A decrease in efficiency of 
certain cytotoxic drugs in hypoxic tumor tissue is also reported, although this effect 
is probably an effect of impaired vascularization of the tissue 68. 
  
3.3. Angiogenesis 
Oxygenation of tumors is facilitated by the creation of new blood vessels. In 
response to hypoxemia, tumors secrete angiogenic cytokines inducing the 
formation of microvessels from the surrounding host vasculature 69. Many studies 
have investigated the role of tumor vessels in context of architecture, constituents, 
genetic abnormalities and angiogenic signaling7 0-72.   
Vascular endothelial growth factor (VEGF) is one of the most important 
angiogenetic cytokines 73. VEGF is the most potent known angiogenic factor with 
specific mitogenic activity on endothelial cells 74. High serum VEGF levels or high 
expression of tumor tissue VEGF are associated with poor prognosis and survival 
in different histological subtypes of lung cancer 75-78. 
Some studies suggest that neoangiogenesis is already present in pre-invasive and 
early invasive bronchial lesions 79-81. This indicates that angiogenesis is a relatively 
early event during lung cancer pathogenesis 79-81. 
Neoangiogenesis is based on sprouting from existing blood vessels. The newly 
formed vessels are leaky and tortuous. The endothelial cell lining of these vessels 
has abnormal morphology and the basement membrane is irregular 82. Treatment 
with angiogenesis inhibitor agents showed an improved survival benefit in a 
number of malignant tumors 83.  
 
3.4. Glycolysis  
Glycolysis is a set of multiple reactions which eventually convert one glucose 
molecule into two molecules pyruvate 84. Glycolysis is a source of energy that 
does not require oxygen and can take place under aerobic or anaerobic conditions 
and is often associated with tumors 85. Hypoxic environment causes activation of 
multiple genes in tumor cells involved in glycolysis, cell proliferation, cell survival, 
angiogenesis, invasion and metastasis, which affect glucose metabolism and other 
associated cellular processes 86, 87. 
Malignant cells exhibit an increased glycolytic flux caused by an over expression 
of glucose transporters GLUT-1 88. Also enzymes that are involved in the glycolytic 
pathway like lactate dehydrogenase (LDH) are elevated 89.  
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Upregulated HIF-1 plays an important role in the expression of glucose 
transporters and glycolytic enzymes 50. The end product of glycolysis is pyruvate 
and, in the presence of LDH 89, it catalyzes the quantitative formation of lactate. 
Lactate in primary tumors may provide a useful metabolic classification for tumors, 
which can serve as a prognostic parameter 90, but data are limited for well-founded 
treatment decision. 
 
4. Treatment of lung cancer 
4.1. Introduction 
Tumor resection is still the first choice of treatment in stage I and II NSCLC 
disease. For patients diagnosed with SCLC or advanced NSCLC, systemic 
treatment (with or without radiotherapy) is the first choice of treatment 91. Systemic 
treatment can be divided into a cellular treatment and an environmental treatment 
response. 
 
4.2. Cellular treatment 
Standard systemic treatment in patients with NSCLC or SCLC is a platinum based 
combination chemotherapy regime 91. Platinum-based chemotherapy agents 
(cisplatin, carboplatin) act by cross-linking subunits of DNA. These agents work 
during any part of cell cycle by impairing DNA synthesis, transcription, and 
function 92. The damaged DNA elicits DNA repair mechanisms, but when repair is 
impossible apoptosis is induced. Platinum-based chemotherapy agents are 
combined nowadays with one of the following chemotherapeutic for a combination 
regime. 
Gemcitabine is a nucleotide analog which replaces one of the nucleic acids during 
DNA replication 93. Hereby, the process arrests tumor growth, because newly 
attached nucleotides are blocked. This process results in apoptosis of the cell.  
Paclitaxel and docetaxel, both antimitotic chemotherapeutics interfere with the 
normal function of microtubulin. Microtubules are responsible for the position of 
chromosomes during their replication and subsequently separation of two new 
cells 94. The result of these chemotherapeutics is inhibition of mitosis. 
Furthermore, paclitaxel and docetaxel induce programmed cell death by binding to 
an inhibitor of apoptosis Bcl2, thereby arresting its function 95. 
Vinorelbine is a semisynthetic vinca alkaloid which also influences microtubule 
function 96.  
Etoposide inhibits the enzyme topoisomerase II 97. Topoisomerase II is essential 
for separation of two new cells at the end of replication. Separation failure leads to 
cell death. 
An additional first line treatment in advanced NSCLC is pemetrexed. Observations 
showed that this multitarget anti-folate pemetrexed in combination with Cisplatin 
was superior to gemcitabin/cisplatin in patients with a non-squamous cell 
carcinoma 19. Pemetrexed is a potent inhibitor of thymidylate synthase and other 
folate-dependent enzymes, including dihydrofolate reductase and glycinamide 
ribonucleotide formyl transferase 21. By inhibiting these enzymes pemetrexed 
prevents the formation of DNA and RNA which are essential in growth and survival 
of normal and cancer cells.  
A second novel therapy of first line treatment is epidermal growth factor receptor 
(EGFR) tyrosine kinase inhibitors (TKIs). EGFR is over expressed in lung cancer 
which leads to an inappropriate activation of the anti-apoptotic RAS signaling 
cascade 98. This leads eventually to uncontrolled cell proliferation. Mutation in the 
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EGFR tyrosine kinase domain is responsible for activation of anti-apoptotic 
pathways 99. EGFR mutations are present in approximately 10% of the western 
patients with NSCLC. The population with a EGFR mutation, treated with EGFR-
TKIs, has shown response rate of 65-82% 98. 
 
4.3. Microenvironment treatment 
Nowadays systemic treatment options which influence the microenvironment have 
been developed. Best known is bevacizumab: an angiogenesis inhibitor, which is a 
humanized monoclonal antibody 24. Bevacizumab blocks VEGF-A thereby 
preventing the growth of new blood vessels. The American Society of Clinical 
Oncology (ASCO) 22 guidelines recommend the addition of bevacizumab to 
carboplatin/paclitaxel in first line cytotoxic therapy, except for patients with 
squamous cell carcinoma, or patients with exclusion criteria prescribed in the 
registration trial 100. 
A number of other agents working on tumor vasculature are under development. 
One of these is ASA404, a tumor vascular disrupting agent which induces 
apoptosis of tumor vascular endothelial cells and cytokine production, leading to 
tumor vascular collapse 101, 102. ASA404 has been studied in a phase II study in 
patients with advanced NSCLC. The median extension of survival was 5 months 
compared to chemotherapy alone 101, 102. A phase III study has finished accrual 
recently.  
An early study with a hypoxic cytotoxin tirapazamine has shown promising results 
in patients with NSCLC 103. Tirapazamine is an aromatic heterocycle di-N-oxide, 
which is activated to a toxic radical only at very low levels of oxygen 104. A phase 
III study (CATAPULT I) showed a benefit of the combination cisplatin and 
tirapazamine over cisplatin alone 105. Unfortunately the next study (CATAPULT II) 
showed no benefit of cisplatin and tirapazamine over cisplatin and etoposide 104. 
  
5. Methods of analyzing in vivo tumor microenvironment  
5.1. Imaging introduction 
Imaging techniques are expanding ever since the development of X-ray and 
bronchoscopy. Nowadays, a numerous amount of techniques have been 
developed to provide information about (pre)malignant lung lesions. The 
conventional techniques have been incorporated in the standard work-up of lung 
cancer detection and staging procedure. More recently a functional imaging 
technique, Positron Emission Tomography (PET), has been incorporated in the 
standard work-up of lung cancer. By imaging metabolic activity, information on 
metastatic spread of the tumor can be obtained. A combination of these imaging 
techniques is able to inform us about the localization of the primary tumor and the 
possibility of lymph or distance metastasis. Recent data showed that PET 
scanning may also be of prognostic value 106-108. Unfortunately, the standard 
imaging techniques, such as X-ray and CT scan, are unable to inform us about the 
microenvironment of the tumor. Therefore functional imaging techniques and 
optical techniques have to be used.  
 
5.2. Imaging techniques that provide information about hypoxia in lung cancer 
5.2.1. Direct measurement of hypoxia 
The present “gold standard” in hypoxia measurements is intratumor polarographic 
measurement of O2 partial pressures using microsensor techniques that adhere to 
the systematic random sampling principle 109-111. The polarographic electrode is 
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not flexible and therefore mainly usable in tumors that are easy to reach like head 
and neck tumors, skin tumors and mamma carcinomas. Only one study with an 
Eppendorf polarographic electrode for per-operative hypoxia measurements has 
been performed in stage I and II lung cancer 112. This study showed that the 
median tumor pO2 ranged from 0.7 to 46 mmHg and was lower than normal lung 
tissue 112. 
 
5.2.2. Reflectance spectroscopy  
5.2.2.1. Introduction 
Light absorption and reflection of tissue is wavelength dependent, and by 
analyzing these absorption and reflection data, information about tissue can be 
obtained. Light absorption in tissue is predominantly by oxy and deoxyhemoglobin. 
Light scattering is caused by various cellular compounds like nuclei, nucleoli and 
mitochondria and extracellular compounds like collagen and elastin 113, 114. 
Reflectance spectroscopy is useful in analyzing malignant tissue 115. Absorption 
and reflectance spectra are susceptible to microenvironmental changes and 
changes in absorption and reflectance spectra have been observed between 
normal and malignant bronchial tissue 115, 116. The development of flexible fibers 
makes delivery of light for absorption and reflection analyses of tissue by a scope 
technique possible. With these flexible fibers spectroscopic analyses could be 
performed in lung tissue during bronchoscopy. To analyze only the submucosa of 
bronchial epithelium, differential path length (DPS) spectroscopy was created 117. 
DPS technique consists of two flexible fibers (figure 1): one delivery-collecting (dc) 
fiber and a collecting (c) fiber. Light travels through the dc fiber and brings light to 
the investigated bronchial tissue. Reflected light is collected by both the dc and the 
c fiber. Reflected light of the dc and the c fiber is then analyzed by a spectrometer. 
Re-emitted light collected by the dc fiber contains superficial and deeper reflected 
light, whereas only deeper reflected light is collected by the c fiber. The subtraction 
of the two spectra data forms the DPS spectra, which contains only superficial 
tissue reflection.  
DPS spectra such as in figures 2 and 3 look very similar to the general picture 
seen in reflection- and elastic scattering spectroscopy: a slight overall decrease in 
signal when going from the blue to the near infrared wavelengths indicating Mie 
scattering and several characteristic absorption bands from blood 118. To translate 
the spectra accurately in terms of biologically relevant parameters it is necessary 
to model the shape of these DPS-spectra and fit these models to the measured 
spectra. To do so, it is possible to analyze what exactly is going on right in front of 
the dc-fiber. However, the part that can be modeled analytically (the diffuse part of 
the light) has been subtracted away. What remains to form the DPS-spectrum is 
that part of the photon distribution for which no analytical models exist. Since 
Monte-Carlo methods do not allow inverse calculations, the only remaining option 
here is empirical modeling. The development of our mathematical model to 
describe the DPS spectra was based on careful analysis of Monte Carlo 
simulations, phantom experiments and a little trial and error. The basic equation 
with which we analyze DPS spectra is:  
                                                     
 
 
           
 eq.1.  
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where µs(λ) stands for the scattering coefficient, µa(λ) for the absorption coefficient 
and τ for the pathlength. Absorption and scattering are wavelength dependent 
functions and in principle the pathlength τ is as well. The pathlength can be 
considered constant.  
 
5.2.2.2. DPS-Measurements in vivo 
Main features 
A typical DPS spectrum measured in vivo is shown in figure 2. Clearly visible are 
the blood absorption dips on a background of Mie Scattering. A fit was made using 
eq 1 on these curves using Mie scattering and blood absorption:  
      
    
 
 
 
          
 
eq.2. 
  
where a and b are Mie scattering parameters, λ0 = 800 nm, ρ the blood volume 
fraction and StO2 the oxygen saturation of the blood. The resulting curve shown in 
figure 2 shows that the model roughly fits the data from 450 nm up. In this fit we 
intentionally ignored the lower wavelengths, because the violet absorption band 
would have seriously worsened the fit.  
Technical improvements to the setup expanding the wavelength range to 350 nm 
yielded an excellent view on the Soret absorption band of hemoglobin but also 
indicated an issue requiring improvement: The Soret absorption band of blood 
around 415 nm appeared to be systematically overestimated by the model. This 
has to do with a phenomenon called pigment packaging. In this wavelength range 
the absorption of hemoglobin in blood vessels is so high that it partly shields itself 
from the incoming light. The intensity of this effect and hence the correction factor 
depends on the “packing diameter”; i.e. the diameter of the areas of high 
concentration. In this case it refers to the diameter of the blood vessels. A 
correction for this phenomenon has been derived and introduced the effective 
absorption coefficient µa’119 where R stands for the radius of the blood vessel. 
      
 
 
 
 
 
           eq.3.  
 
This correction assumes packing of the absorber in cylinder shaped vessels. A 
slightly different correction can be derived for different packing shape120. Our 
cylinder approach may become problematic if we go from cylindrical micro vessel 
to the smallest capillary where single red blood cells pass from time to time. Not 
only do the red blood cells have complicated non cylindrical shapes, they also 
change shape continuously while passing through the smallest capillaries. Hence, 
for simplicity, and because it seems to fit well we use the cylindrical correction 
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factor even for diameter values that suggest single red blood cells rather than a 
well filled cylindrical vessel. This is important to keep in mind when interpreting the 
values of this parameter. 
The packing effect is not limited to hemoglobin, but affects all absorbers present in 
the blood vessel. Any other vascular absorber can be added to the absorption of 
hemoglobin and oxyhemoglobin before the packing correction is performed. Any 
absorber that is homogeneously distributed over the tissue can be added after the 
packing correction: 
  
                   
 
 
 
 
 
 
eq.4. 
 
where µaother stands for the other vascular absorbers and  µahom for an additional 
homogeneously distributed absorber. The resulting fit and the residue spectrum for 
a typical measurement are shown in figure 3. Judging from the values of χ2 we 
have a much better fit here (significantly better at p<0.05 F-test) when looking at 
the entire wavelength range. As expected the improvements are limited to the 
<450 nm band.  
 
5.2.3. 18F-fluoromisonidazol and Positron Emission Tomography 
Hypoxia imaging by PET is possible. This has been introduced by a class of 
probes called hypoxic markers 121. These hypoxic markers seem to be able to bind 
to hypoxic cells. Several hypoxic markers have been investigated 85, 121. Most 
widely used and investigated is tracer 18F-fluoromisonidazol (18F-FMISO), it 
contains 2-nitroimidazoles which have maximum binding to hypoxic cells 122, 
123
.18F-FMISO enters cells by passive diffusion. In cells with reduced tissue 
oxygen partial pressure it is reduced by nitroreductase enzymes to become 
trapped 124. When oxygen is abundant in normally oxygenated cells, the parent 
compound is quickly regenerated by re-oxidation and metabolites do not 
accumulate 124. However, in hypoxic cells, the low oxygen partial pressure 
prevents re-oxidation of 18F-FMISO metabolites, resulting in tracer accumulation 
in hypoxic cells. Because 18F-FMISO only accumulates in hypoxic cells with 
functional nitroreductase enzymes, 18F-FMISO only accumulates in viable cells 
but not in dead necrotic cells 124. 
Comparisons between direct hypoxic measurement by the Eppendorf 
polarographic electrode and 18F-FMISO have been performed 125, 126. Difference 
in accuracy was observed between different type of tumors. Measurement 
between head and neck tumors measured by the Eppendorf polarographic 
electrode and 18F-FMISO had the highest correlation 125. Due to the difficulty of 
measurement of lung tumors by the Eppendorf polarographic electrode, no data 
are present. 18F-FMISO has been studied to predict treatment response and 
survival in patients with NSCLC 124, 127, 128. 
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5.3. Imaging techniques that provide information about vascular patterns  
5.3.1. Narrow Band Imaging 
The Narrow Band Imaging (NBI) technique is based upon a light source with 
sequential red-green-blue (RGB) illumination 129. The NBI system has special RGB 
filters of which the band-pass ranges have been narrowed from the standard 400-
700nm (B 400-500nm, G 500-600nm and R 600-700nm) to 400-590nm (B1 400-
430nm, B2 420-470nm and G 560-590nm) 129. Also, the relative contribution of 
blue light (B1) has been increased. With this choice of filters NBI enables 
enhanced visualization of the mucosal morphology. Blue light allows optimal 
superficial imaging due to its small penetration depth 129, 130. Blue light is also a 
main chromophore of haemoglobin in bronchial tissue. Haemoglobin has a 
maximum absorption wavelength near 415 nm. Because Narrow band imaging-
Blue 1 (NBI-B1) covers the absorption wavelength for haemoglobin, a more 
accurate detection of the superficial vessel structures can be obtained 131. The 
biological hypothesis is that the microvascular patterns of (pre)malignant lesions 
are different from that of normal bronchial mucosa 79, 80, 132. Clinically, 
microvessels, vascular networks and dotted vessels were observed with NBI, and 
histological biopsies of areas with dotted vessels showed premalignant lesions 
and angiogenetic squamous dysplasia (ASD) 130. 
5.3.2. DCE-MRI and DCE-CT                   
Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) can be used 
to evaluate tissue vascularization 133. By using an injection with paramagnetic 
contrast agent, like gadolinium, increase signal intensity of blood on T1-weighted 
images can be seen 133. All tissues with an adequate blood supply will enhance, 
but malignant areas, with abnormal microvessels and increased permeability, tend 
to have increased signal intensity 133. Quantitative related data of tissue perfusion 
and microvessel permeability can be obtained by calculating the concentration of 
gadolinium in the region of interest. The relation between the changes of signal 
intensity is non-linear and therefore not easy to define 134. Limited results have 
been achieved in lung malignancies. Motions by the heart and lungs, and a low 
signal to noise ration due to the small amount of lung tissue, makes it difficult to 
obtain adequate images. An alternative modality is dynamic contrast-enhanced 
computer tomography (DCE-CT) also known as perfusion CT. The relation 
between contrast concentration iodine and enhancement is straightforward with 
CT, making it easier to use 134.  
5.3.3. Sonography of mediastinal lymph nodes 
Sonography is not a regular tool in the detection of lung cancer. It is mostly used in 
easy reachable malignancies like head and neck tumors. The introduction of echo 
Doppler provides more information about the vascularization of a tumor 135-137. By 
using the sonographic option of the EUS-FNA and EBUS, it is possible to obtain 
vascular information of mediastinal lymph nodes.  Previous studies showed that 
lymph node metastases had systematic effects on the vascular patterns within the 
node 136, 138.  Aberrant vessels, displacement of vessels, and avascular areas in 
the center of the node were observed, indicating a compromised vascular network 
within the center of the node 136, 138. 
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5.4. Imaging technique that provide information about the glycolysis 
5.4.1. Positron Emission Tomography  
Positron emission tomography (PET) is a non invasive imaging technique which is 
able to provide physiological information of the body 139. Positron-editing 
radionuclide (tracer) can be introduced into the body on a biological active 
molecule. Pairs of gamma rays that are emitted indirectly by the tracer can be 
detected by a PET scan. [18F]Fluorodeoxyglucose (18F-FDG) is the most 
commonly used tracer in clinical oncology. This tracer is a glucose analog that is 
taken up by glucose-using cells 140. Once 18F-FDG has entered a cell it is 
phosphorylated by hexokinase to deoxyglucose 6-phosphate 140. The next step in 
the glycolysis, the production of deoxyfructosis 6-phosphate, is not possible 
because the oxygen atom, which is replaced by F-18 to generate 18F-FDG, is 
required for the next step in glucose metabolism in all cells 140. Therefore no 
further reactions occur in 18F-FDG and 18F-FDG is trapped in the cell 140. This 
results in intense radiolabeling of tissues with high glucose uptake, such as the 
brain, the liver and most cancers 128, 141. A high uptake of 18F-FDG reflects an 
increased glucose metabolism141. 
Computed tomography (CT) used to be the standard imaging technique for the 
analysis of lung cancer. Over the past decade 18F-FDG-PET has proved to be a 
valuable imaging technique in the standard work-up of NSCLC 142.  The additional 
information gained was detection of lesions initially not seen on CT-scan 143. 
Moreover, in tumor staging of patients with NSCLC, analysis of integrated PET/CT 
images was superior to that of CT images alone, PET images alone, and PET and 
CT images viewed side by side 144-146. 
The concentration of 18F-FDG in a cell can be quantified by a standard uptake 
value (SUV). This can be calculated as shown by equation 5 147.  
     
 
 
 
 
 
              
 eq. 5. 
 
In this equation the SUV is dependent on the Average activity Concentration in the 
specific volume of interest (ACvoi), Dose of 18F-FDG (FDGdose) and Body weight 
(BW). SUV is a simplified quantitative measurement which can be seen as a 
metabolism parameter. SUVmax, the maximum of 18F-FDG concentration, showed 
to be a prognostic and predictive marker in patients with stage I or II NSCLC 107, 
108, 148
. Physiology as well as technical factors can affect the SUV outcome 147. 
Many of these factors have only a relatively small effect; however an accumulation 
of these factors can lead to substantial differences 147. Technical factors include: 
incorrect synchronization of clocks of PET/CT camera and dose calibrator, 
paravenous administration of 18F-FDG, and residual activity in administration 
system 147. Some physiological factors are: blood glucose level of the patient 149, 
patient comfort 147, and inflammation 150.  
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Figure 1: basic DPS geometry: two optical fibers tightly together in contact with the tissue. One 
delivering light (d), and both collecting light (c) 
CoreCladding
c-fiber
dc-fiber
tissue
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Figure 2. Typical DPS spectrum measured endoscopically on normal bronchial mucosa with fit of 
the model of equation 2 and noise weighed residues 
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Figure 3. Typical DPS spectrum measured endoscopically on normal bronchial mucosa with fit of 
the model of equation 4 and noise weighed residues 
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Aim of the thesis 
 
The aim of this thesis was to investigate optical and functional imaging in patients 
with lung cancer. In this thesis reflectance spectroscopy and Positron Emission 
Tomography were studied. The use of reflectance spectroscopy in the analysis of 
patients diagnosed with endobronchial tumors was studied in the first place. For 
this study a fiberoptic instrument was used which can be utilized for DPS 
measurements during bronchoscopy. To obtain reflectance spectroscopic 
measurements in mediastinal lymph nodes a single fiber optical probe which could 
be used for reflectance spectroscopy measurements during EUS-FNA was 
constructed. Furthermore the use of PET scanning in patients diagnosed with 
SCLC was studied.   
In chapter 2 the available optical techniques for detection of premalignant lesions 
in the central airways were described and the techniques were divided into 
different categories. We set out the technical aspects of the imaging and point 
measurement techniques. Furthermore the underlying biological mechanisms 
resulting in the optical contrast for each technique, and the clinical use of these 
novel optical techniques were discussed. Reflectance spectroscopy seemed to be 
a promising technique for imaging and physiological studies; further research with 
this technique was performed. 
In chapter 3 the microvascular data obtained by DPS was compared to the 
expression of a hypoxia related protein: HIF1a. HIF1a is a well-known and often 
used protein in tumor hypoxia related studies. A significant correlation between a 
low microvascular saturation measured by DPS and an elevated expression of 
HIF1a was observed, concluding that hypoxia related data can be studied by DPS. 
As hypoxia is related to aggressiveness of malignant diseases, in chapter 4, the 
relation between the peripheral microvascular saturation measured by DPS in the 
different types of lung cancer was reported. No differences were found between 
NSCLC and SCLC, but differences between the four subtypes were found instead. 
Peripheral microvascular saturation of adenocarcinomas and squamous cell 
carcinomas was higher compared to large cell carcinomas and SCLC. Observed 
differences suggested a poor vascular pattern in poor differentiated tumors. No 
survival variation between the microvascular saturation data was seen.  
Whether the reflectance spectroscopy technique could be useful in other 
diagnostic techniques was unknown and the possibilities were explored in chapter 
5. An original optical instrument was developed for the analysis of lymph node 
optical properties. A single fiber probe was constructed to guide through an EUS-
FNA needle to obtain reflectance spectra in mediastinal lymph nodes during EUS-
FNA procedure.  
In chapter 6 the feasibility of reflectance spectroscopy in lymph nodes during 
EUS-FNA procedure was described. The procedure without complications was 
performed in 10 patients. Differences in spectra were observed between normal 
and malignant lymph nodes. Decreased blood volume fraction and microvascular 
saturation were seen in malignant lymph nodes. 
In the future optical imaging techniques will probably become more important in 
detection and staging of (pre)malignancies. Because optical imaging techniques 
can provide information about the microenvironment of a malignancy, optical 
imaging techniques might have predictive and prognostic value. Functional 
imaging, especially PET scanning, can be implemented in this respect. Perhaps a 
combination of these two modalities works additively. To study the value of 
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functional imaging, research was conducted with PET scanning in patients 
diagnosed with SCLC.  
In chapter 7 the value of PET scanning in detection of metastatic soft tissue 
lesions in patients diagnosed with SCLC was investigated, since this modality is 
not a standard procedure in the work-up of SCLC patients yet. PET scanning was 
responsible for change of stage in 7.9% of the 63 patients. We concluded that PET 
scanning has an additive value in the staging work-up of patients diagnosed with 
SCLC. 
In chapter 8 the value of SUVmax in 75 patients with SCLC was examined and 
the conclusion was that the SUVmax value of the primary tumor was lower in 
patients diagnosed with LD compared to ED. Furthermore, the SUVmax value 
showed to be a predictive factor in the PFS and OS in patients with ED. In this 
patient group high SUVmax was correlated with a better PFS and OS compared to 
patients with a low SUVmax value. These results were not observed in LD 
patients.  
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Abstract 
Current routine diagnosis of premalignant lesions of the central airways is 
hampered due to a limited sensitivity (white light bronchoscopy) and resolution 
(Computer tomography (CT), Positron Emission Tomography (PET)) of currently 
used techniques. To improve the detection of these subtle mucosal abnormalities, 
novel bronchoscopic optical imaging techniques have been developed over the 
past decade. In this review we highlight the technological developments in the field 
of endoscopic imaging, and describe their advantages and disadvantages in 
clinical use.  
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1. Introduction  
Lung cancer is the second most common cancer in men and women, and the 
leading cause of cancer related death. In industrialized countries, the mortality rate 
of lung cancer is higher than of breast, colorectal and prostate cancer combined 
(1). Lung cancer is divided in small cell lung cancer (SCLC) and non small cell 
lung cancer (NSCLC). NSCLC is subdivided in 3 different major histological 
classes: squamous cell carcinoma (SCC), adenocarcinoma and undifferentiated 
large cell carcinoma(2). Fifty years ago Auerbach et al discovered that preinvasive 
lesions of different grades of severity were associated with lung tumors of 
squamous cell histology. This observation lead to the hypothesis that SCC arises 
from these preinvasive changes (3). It was shown that SCC develops sequentially: 
from normal to metaplasia, dysplasia, carcinoma in situ (CIS) and eventually 
invasive carcinoma (4). Early detection of preinvasive lesions is important because 
local treatment can preclude patients from getting invasive cancer. Local treatment 
have been developed and include photo dynamic therapy (PDT)(5-7), 
electrocautery(8), brachytherapy(9) and cryotherapy(10). Treatment with PDT has 
extensively been investigated. PDT showed in 99 patients with stage 0 and 56 
patients with stage IA disease a complete response of 86%. Especially success 
response  was seen in lesions smaller than 1 cm (complete response 95%) (11).   
Since the epithelial changes associated with premalignancy are very subtle, no 
current routine imaging technique is sensitive enough to detect these lesions. Non-
optical imaging techniques such as ultrasound, Magnetic resonance imaging 
(MRI), Computer tomography (CT), Positron Emission Tomography (PET) do not 
have a sufficient spatial resolution to detect the subtle mucosal abnormalities. 
Currently, premalignant lesions are only detected by bronchoscopy. 
Unfortunately, the sensitivity and specificity for the detection of premalignant 
lesions is low using standard white light bronchoscopy (12). Therefore, novel 
endoscopic imaging techniques have been developed over the past decade to 
increase its sensitivity. Furthermore, optical point (spectroscopic) techniques have 
been developed to increase the specificity of the imaging modalities. In this review 
we describe the technical aspects of these imaging and point measurement 
techniques, discuss the underlying biological mechanisms resulting in the optical 
contrast for each technique, and discuss the clinical use of these novel optical 
techniques.  
 
 
2. Biological changes 
2.1. Morphology 
SCC is mainly located in the central bronchial tree of the lung.  This has been 
associated with cigarette smoke exposure and the higher concentration of 
carcinogens in the more central airways. The lesions are mainly located on the 
bifurcation segment bronchi but no predominant place within these central airways 
is present. Comparable to the development of malignant lesions in other organs 
like oesophageal cancer by chronic inflammation due to bile acid irritation and 
cervical cancer by chronic Human Pappilomavirus (HPV) inflammation (13), lung 
cancer development seems to be driven by chronic irritation mostly due to 
smoking(14, 15) but also HPV inflammation(16). As result of chronic 
irritation/stimulation cells may differentiate towards a phenotype better adapted to 
the prevailing environment, and squamous metaplasia occurs (17). 
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It is believed that SCC develops according a stepwise process which can be 
observed with histological biopsies (4).  Hyperplasia and metaplasia are thought to 
be reactive lesions, with goblet cell hyperplasia and basal cell hyperplasia. 
Dysplasia is considered as a true preneoplastic lesion and may vary in degree, 
from mild to moderate and severe. Mild dysplastic lesions are characterized by 
minimal architectural and cytological disturbance. Moderate dysplasia exhibits 
more cytological irregularity, which is even more pronounced in severe dysplasia. 
In severe dysplasia it is accompanied by cellular polymorphism. In a subset of 
dysplastic changes, angiogenetic squamous dysplasia (ASD), the basal 
membrane thickens and there is vascular growth in the subepithelial tissues that 
results in papillary protrusions (18, 19). The observed cellular changes include 
modifications in the volume, form, and orientation of the nuclei, an increase in 
nucleus chromatin content, variations in the nucleus-cytoplasm ratio, and changes 
in the intra-cytosolic content (20). Also major architectural changes occur, such as 
a disorganized fibered network microstructure (21), and reticular basement 
membrane thickening (22), inducing a thickening of the epithelial layer. 
 
2.2. Physiology 
In several types of solid cancers, hypoxia has been reported as a key factor in the 
aggressiveness of a tumor (2, 23). Heterogeneous distribution of oxygen and 
nutrients within the tumor has been related to invasive growth (24). Some 
evidence exists that hypoxia is an early step in carcinogenesis (22, 25, 26), but for 
early lung cancer this has not been investigated. We did observe hypoxia in later 
stages of endobronchial cancer, but this cannot be extrapolated to premalignant 
disease (27).  
Oxygenation of solid tumors is facilitated by the creation of new blood vessels 
(neoangiogenesis). In response to hypoxia, tumours secrete angiogenic cytokines, 
such as vascular endothelial growth factor (VEGF), inducing the formation of 
microvessels from the surrounding host vasculature (28).  Some studies suggest 
that neoangiogenesis is  present in preinvasive and early invasive bronchial 
lesions, indicating that angiogenesis is an early event in lung cancer 
carcinogenesis (18, 29, 30). Fisseler-Eckhoff et al found an increasing vessel 
count in the bronchial mucosa when progressing from inflammation to hyperplasia, 
metaplasia, moderate dysplasia, severe dysplasia and carcinoma in situ (29). 
Angiogenetic squamous dysplasia (ASD) was identified in dysplastic bronchial 
epithelium (18, 19) as well. Whether or not ASD is an indicator of progression to 
invasive carcinoma is undetermined (31). Furthermore, whether an increase in 
vascularisation is related to progression of a lesion to malignancy and whether it is 
driven by hypoxia remains to be elucidated.  
Recently, Meert et al did not find significant differences in microvessel count 
between different stages of premalignant bronchus carcinoma. However, they did 
find an elevated expression of neoangiogenetic proteins in premalignant lesions 
(32). Furthermore, the use of vessel density to characterize premalignant lesions 
is limited because other biological factors such as infections, or chronic obstructive 
pulmonary disease, may increase the vessel density as well. In conclusion, the 
vasculature appears to be altered in premalignant disease but data are not uniform 
and no differentiation between changes in vessel density due to premalignant 
disease or due to other biological causes can be made. 
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2.3. Biochemistry 
Hypothetically, the cellular metabolic activity is elevated in premalignant lesions, 
leading to intracellular changes in the concentration of nicotinamide adenine 
dinucleotide (NADH) and/or nicotinamide adenine phosphor dinucleotide 
(NADPH), which are both fluorescent molecules. In cancerous bronchial cells, a 
decreased fluorescence intensity of NADH and NADPH has been reported (33, 
34). Of note, these studies were performed in vitro, and translating these results to 
an in vivo environment is difficult, as discussed in section 3. 
 
 
3. Detection of premalignant lesions: wide-field optical imaging 
Based on the possible biological mechanisms involved in early carcinogenesis, 
different techniques have been developed to detect premalignant lesions with 
higher sensitivity and specificity than white light bronchoscopy. Detection of 
premalignant lesions is usually performed in a wide-field imaging mode due to the 
large size of the bronchial tissue area that has to be investigated. In the following 
section we will discuss the technical aspects of the imaging techniques, relate the 
technology to the biological aspects of lung carcinogenesis, and discuss the 
clinical use of the techniques. 
 
3.1. Autofluorescence imaging 
Autofluorescence bronchoscopy is the most widely used and investigated 
technique in the detection of premalignant bronchus lesions. Several 
autofluorescence devices are available. The LIFE (Lung Imaging Fluorescence 
Endoscopy) is the first and best known autofluorescence bronchoscope (35-44). 
first published by Lam et al. (12). Other devices such as the D-light 
autofluorescence (45-47) , Pentax-SAFE 1000 (48) and its successor the Pentax 
3000 (11, 49, 50)  are similar in its use. 
Autofluorescence imaging uses the natural fluorescence properties of the tissue 
itself, i.e. no exogenous contrast agents have been applied. When a natural 
fluorophore is excited to a higher electronic state by absorption of a photon of an 
appropriate wavelength, the fluorophore may return to its ground electronic state 
by emission of a photon of a higher wavelength (fluorescence). When the 
bronchial surface is illuminated with blue light (wavelengths ranging from 400-450 
nm), the fluorescent light of a higher wavelength (>450 nm, i.e. green and red) can 
be visualised using long pass filters that block the excitation light but transmit the 
higher wavelength fluorescent light. Since autofluorescence imaging is performed 
in a wide-field non-contact imaging mode, the detected fluorescent photons 
originate from various depths of tissue. The detected fluorescence consists of 
contributions from fluorophores that are involved in cellular metabolic processes 
such as nicotinamide adenine dinucleotide (NADH) and flavins (FAD) or are 
associated with their structural matrix (keratin, elastin and collagen). In a wide-field 
imaging mode, it is expected that the latter fluorophores are the dominant 
contributors to the signal. Furthermore, spectral distortion of the measured 
fluorescence arises due to the scattering properties of tissue and absorption of 
both the excitation light and emitted fluorescence by tissue chromophores 
(specifically, hemoglobin). As a consequence, the optical contrast between 
premalignant and normal bronchial tissue using autofluorescence imaging is 
based on a combination of the three different biological mechanisms 
(biochemistry, physiology and morphology). First, the local concentrations of 
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natural fluorophores involved in cellular metabolism such as NADH may change in 
premalignant tissues (51). However, since the dominant source of detected 
fluorescence is the structural matrix, this is not very likely to yield large contrasts. 
Second, an increased blood supply in the adjacent lamina propria is likely to play a 
key role in the reduction of autofluorescence in premalignant tissues, and thus in 
the generation of the autofluorescence contrast in bronchial tissues (52). However, 
since other biological factors such as infections, or chronic obstructive pulmonary 
disease, may increase the blood supply as well, this contrast is not likely to be 
very specific. Third, epithelial thickening will cause less excitation light to reach the 
structural matrix, thereby also reducing the detected fluorescence. Based on these 
biological mechanisms, premalignant tissue is expected to show reduced 
autofluorescence, but this effect will not be very specific. 
These considerations are generally confirmed in clinical studies. Autofluorescence 
bronchoscopy was shown to increase the sensitivity for detection of premalignant 
bronchial lesions, but is hampered by a low specificity (35-44, 46, 47). Difficulties 
exist in distinguishing benign epithelial chances such as bronchitis and 
inflammation from precancerous lesions. Studies have demonstrated about two 
third of the lesions to be false positive results after correlation with pathology (38, 
53, 54).  
A number of modified versions of autofluorescence imaging have been introduced, 
which rely on the same principles of autofluorescence imaging but introduce 
additional filter sets to enhance the specificity of the images to the mucosal blood 
supply. The autofluorescence imaging bronchovideoscope system (AFI, Olympus) 
displays a composite image integrating autofluorescence with filtered reflected 
green and red light; the reflected green light is sensitive to mucosal blood due to 
the high absorption of green light by blood, whereas the reflected red light is 
basically unaffected by the presence of blood (55). In a study including 32 patients 
sensitivity of detecting dysplasia by AFI was 96.7%, specificity was 83.3 % (55). 
An other study, including 31 patients, sensitivity of detecting severe dysplasia or 
worse with AFI was 94.7% and the specificity was 71.1% (56). 
The Onco-LIFE device contains a white light and a fluorescence mode. In 
fluorescence mode, the device uses blue light (395-455nm) and small amount of 
red light (675-720nm) from a filtered mercury lamp arc lamp for illumination. The 
camera captured and combines the fluorescence green light and the reflected red 
light and displays it on a normal color video monitor. The green fluorescence light 
will change in places with bronchial pathology; the red reflected light is not affected 
by tissue pathology. Illuminated normal bronchial epithelium by blue light, 
fluoresces in green. When blue light is illuminated on abnormal bronchial 
epithelium it transforms through different grades of dysplasia into a progressive 
decrease in green fluorescence due to increased epithelial thickness and 
vascularization making these abnormal areas appear red. Red light is less 
absorbed by hemoglobin and therefore less influenced by changes in vascularity 
associated with inflammation (57). The red reflected light can therefore be a 
reference for different light intensities from changes in angle and distance of the 
bronchoscope to the bronchial surface. Combining the reflected and fluorescence 
images enhances the contrast of normal, premalignant and malignant bronchial 
tissue (57). It is possible to analyse the Red/Green (R/G) ratio in the central 
portion of the displayed image providing quantitative data. Combining the data of 
two medical centers, 738 individuals underwent a bronchoscopy with the Onco-
LIFE device. The corresponding R/G ratio increased when the premalignant 
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lesions became more malignant. Validated data showed that R/G ratio of 0.54 had 
a 85% sensitivity and a 80% specificity for the detection of high grade and 
moderate dysplasia (58). The concept of color fluorescence ratio is not device 
specific, and can be integrated into any reflectance fluorescence imaging system. 
Lee et al introduced real time dual video and autofluorescence bronchoscopic 
imaging (59), allowing to display both video and autofluorescence bronchoscopic 
images of the target simultaneously. This hypothetically makes it easier to identify 
benign lesions such as bronchitis, although the biological mechanism behind this 
hypothesis is not clear. Dual band imaging has been studied in only one study, 
reporting a sensitivity and specificity in detection of preneoplastic lesions 0.86 and 
0.94,  respectively (59). However, sample size in that study was relatively small; 
secondly, it was not a comparative study where individual imaging modalities 
(video and AF bronchoscopy) were assessed independently before dual imaging.  
The recently introduced color fluorescence endoscopic system, PDS-2000, uses a 
color intensified charge coupled device (ICCD) (60) instead of a regular CCD, but 
the advantages of such a device are not clear. In a clinical study, sensitivity and 
specificity were 89.2% and 52.6%, respectively, while for white light bronchoscopy 
these numbers 54.1% and 77.7%, respectively. No studies comparing color 
fluorescence bronchoscopy and autofluorescence bronchoscopy have been 
performed. 
 
3.2. Narrrow band imaging 
Shibuya et al developed narrow band imaging (NBI)(31). The NBI-system 
(Olympus Corp, Tokyo, Japan) is based upon a light source with sequential red-
green-blue (RGB) illumination. White light from a Xenon lamp is passed through a 
rotary RGB filter that separates the white light into the colors red, green, and blue, 
which are used to sequentially illuminate the mucosa. The red, green, and blue 
reflected light is detected separately by a monochromatic charged coupled device 
(CCD) placed at the tip of the endoscope, and the three images are integrated into 
a single color image by the video processor (31). In addition to the conventional 
RGB filters for white light endoscopy, the narrow band imaging system has special 
RGB filters of which the band-pass ranges have been narrowed from the standard 
400-700nm (B 400-500nm, G 500-600nm and R 600-700nm) to 400-590nm (B1 
400-430nm, B2 420-470nm and G 560-590nm) (61). Also, the relative contribution 
of blue light (B1) has been increased. With this choice of filters, NBI enables 
enhanced visualization of the mucosal morphology because blue light allows for 
optimal superficial imaging due to its small penetration depth. Secondly, because 
Narrow Band Imaging filter B1 covers the absorption maximum for hemoglobin, a 
detailed image of the superficial vessel structures can be obtained. The NBI filter 
can be manually enabled and disabled during endoscopy making it easy to switch 
between the standard mode and the NBI-mode. The biological hypothesis driving 
the development of NBI is that the microvascular patterns of premalignant lesions 
are different than of normal bronchial mucosa (31).In contrast to autofluorescence 
imaging, which is predominantly sensitive to total mucosal blood volume, NBI is 
sensitive to microvascular patterns with high spatial resolution, making the image 
contrast complementary to autofluorescence imaging (62, 63). Clinically, 
microvessels, vascular networks and dotted vessels were observed with NBI, and 
histological biopsies of areas with dotted vessels showed premalignant lesions 
and ASD (64). NBI detected five instances of dysplasia or cancer (23% of all 
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included patients) that were not detected with normal with light bronchoscopy (p< 
0.005).  
 
 
4. Improving the specificity of imaging: point (spectroscopic) techniques 
Novel imaging modalities increase the sensitivity for detection of premalignant 
bronchial lesions, at the cost of a low specificity. Difficulties exist in distinguishing 
benign epithelial chances such as bronchitis and inflammation from precancerous 
lesions. To increase the specificity of the imaging modalities, additional optical 
methods have been developed to be used in conjunction with wide-field imaging. 
These techniques provide more detailed information about small tissue 
areas/volumes; information that may be used to classify a suspicious lesion as 
either premalignant or benign. Although all technologies discussed in the next 
section are point-techniques, they are categorized here as point-imaging or point-
spectroscopic techniques. 
 
 
Point Imaging 
4.1. Fibered Confocal Fluorescence Microscopy 
Fibered Confocal Fluorescence microscopy (FCFM) is a technique that can be 
used to image the microscopic structure of the bronchial wall (21). It is based on 
the principle of confocal microscopy, which provides a clear, in-focus image of a 
thin section within a biological sample by a flexible fiberoptic miniprobe.  
The 1-mm diameter fiberoptic probe, which can be introduced into the working 
channel of a flexible bronchoscope, produces images from a layer of 0 to 50 µm in 
depth below the bronchial surface, with a lateral resolution of 5 µm, and a field-of-
view up to 600 µm in diameter (21). This ultra high magnification system provides 
the endoscopist a cross-sectional image of the bronchial mucosa epithelium, 
resulting in images similar to histology during bronchoscopy (65, 66). Basement 
membrane and upper submucosa can be made visible with a nice quality. 
Thiberville et al tested FCFM in twenty-nine high risk patients for lung cancer 
underwent an autofluorescence bronchoscopy. A specific pattern of the bronchial 
wall microstructure could be observed in some precancerous conditions showing a 
disorganised fibered network. This was observed in one invasive cancer, three 
CIS, two mild and one moderate dysplastic and three metaplastic lesions (21). 
However, the absent of visualisation of epithelial cells, resulted in a difficulty of 
true differentiation of the premalignant bronchial lesions (65). By adding an 
exogenous nontoxic fluorophore agent, such as methylene blue, reproducibility 
imaging of the epithelial cells could be obtained (66). Future studies have to show 
whether FCFM with methylene blue is possible to differentiate between normal, 
premalignant and malignant bronchus lesions.  
FCFM can be easily performed during a bronchoscopy under local anaesthesia. 
The miniprobe can be guided through the working channel of the bronchoscope. 
Interpretation of FCFM images of premalignant lesions relies on the fluorescence 
properties of the imaged tissue. Because the obtained images are similar to 
histology, the scopist must know the characteristics of premalignant histology to 
draw conclusions. 
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4.2. Optical coherence tomography 
Optical coherence tomography (OCT) is an optical imaging modality that performs 
high-resolution, cross-sectional, subsurface tomographic imaging of the 
microstructure of tissues (67). It has been used to image subsurface tissue 
morphology in several other fields (68-75).The physical principle of OCT is similar 
to that of B-mode ultrasound imaging. Instead of using sound waves, near-IR light 
is passed into the tissue, and by detecting the reflected light as it interacts with 
tissue structures as a function of depth, a cross-sectional image is created through 
optical interferometry (76). In principle, OCT is capable of imaging the morphology 
of mucosal lesions. OCT is possible with an OCT probe with an outer diameter of 
1.5mm and a depth focus of 3mm. It is possible to insert it in a working channel of 
a bronchoscope.  For adequate subsurface tissue imaging, the OCT must be 
positioned closely to the airway wall. Images are real-time monitored. 
Tsuboi et al suggested that in situ and invasive carcinoma can be distinguished 
from normal bronchial epithelium (77). Lam et al concluded that autofluorescence 
endoscopy–guided OCT imaging of bronchial lesions is technically feasible, and 
may be a promising nonbiopsy tool for in vivo imaging of preneoplastic bronchial 
lesions (78). 
Interpretation of the OCT imaging is complex and experience is required. To 
analyze the images and to differentiate between inflammatory and premalignant 
lesions, it is necessary to know more about the histopathology images of 
premalignant lesions. It seems that differentiation between different premalignant 
stages can be quantified by measurement of the epithelial thickness (78). The 
epithelial thickness was significantly different between invasive cancer and CIS. 
Also the epithelial layer of mild, moderate and severe dysplasia lesions was 
significantly thicker than of metaplastic lesions.  
The detection rate of premalignant lesions by OCT is probably related to the skills 
of the bronchoscopist and the individual imaging interpretation. Unfortunately the 
availability of OCT is limited due to the limitations of the current research results 
and the high costs of the equipment.  
 
4.3. Endo-Cytoscopy System (ECS) 
A recently introduced endoscopic microscopic technique is the Endo-Cytoscopy 
System (ECS) that enables microscopic imaging of the tracheobronchial tree (79).  
ECS is able to magnify up to x450 on a video monitor. By staining areas of interest 
with methylene blue, high magnification imaging was possible. Images 
corresponded with the light microscopy. With this technique in vivo discrimination 
between normal and dysplastic lesions is possible. A limitation of the technique is 
that contact with the bronchial tree is necessary, which may cause bleeding, 
hampering a clear view. Unfortunately, no clinical data are available at the 
moment.  
 
Point spectroscopy 
4.4. Autofluorescence spectroscopy 
Autofluorescence spectroscopy (AFS) works similar to autofluorescence imaging, 
but instead of visualising the remitted fluorescence of a large tissue area using a 
CCD camera with only a few wavelength bands (mostly red and/or green), the 
remitted fluorescence of a small tissue area is coupled (usually with a fiber) into a 
spectrometer which resolves the fluorescence into a complete spectrum (80). 
However, AFS suffers from the same problems as autofluorescence imaging: it 
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cannot discriminate between premalignant and benign disease such as bronchitis 
and inflammation (80).  
 
4.5. Reflectance spectroscopy  
The absorption and scattering coefficients of tissue are wavelength-dependent and 
their value at each wavelength reflects the probability that a photon will be 
absorbed or scattered by the tissue. The absorption coefficient is given by the 
product of the extinction coefficient and the concentration of dominant tissue 
chromophores such as oxygenated hemoglobin (HbO2) and deoxygenated 
hemoglobin (Hb), bilirubin, betacarotene, water, and lipids. The absorption 
coefficient is therefore also related to physiological parameters such as total 
hemoglobin concentration (THb=HbO2+Hb) and blood oxygen saturation 
(StO2=HbO2/THb).  Scattering in tissue originates from spatial heterogeneities of 
the optical refractive index that occur on size scales ranging from a few 
nanometers to a few millimeters. Since these refractive index fluctuations depend 
on the concentration and type of tissue constituents, the light scattering signature 
(both the light scattering amplitude and wavelength dependence) is sensitive to 
the microarchitecture of the tissue and can be used for tissue diagnosis. 
Differential path length spectroscopy (DPS) is a novel reflectance spectroscopic 
technique developed for the purpose of studying the superficial layer of the 
bronchial mucosa (27, 81-83). DPS utilizes a unique fiber-optic geometry to 
selectively sample photons that have propagated shallow depths into tissue, 
making it very suitable for the classification of superficial lesions such as 
preneoplasias. In DPS the path length is approximately equal to the fiber diameter, 
independent of absorption and scattering. This fiber geometry overcomes the 
classical limitation of unknown photon path length during diffuse reflectance 
measurements; this allows real-time quantitative information (THb, StO2) to be 
extracted from DPS measurements. Using DPS we have measured a significant 
difference in THb and StO2 between normal tissue and cancerous tissue. 
However, no significant differences in these parameters were found between 
normal and premalignant tissues (82), although the number of truly premalignant 
lesions (dysplasia, CIS) included in that study was very low. 
Zeng et al used an integrated endoscopy system for simultaneous imaging and 
spectroscopy. This system is capable of obtaining white-light bronchoscopy, 
autofluorescence bronchoscopy and both reflectance and fluorescence 
spectroscopy without introducing optical fibers through the working channel (84). 
The advantage of this technique is the non-contact procedure.  The integrated 
endoscopy system was tested in 63 patients and showed that the experimental 
system was able to provide identical spectra to those obtained by  fiber-optic 
probes (85). Significant differences of reflectance and fluorescence spectra from 
malignant tissue compared to normal lung tissue were observed.  Due to the 
limited numbers of premalignant lesions, no information of improving the sensitivity 
or specificity of detection of premalignant lesions could be presented.  
 
Discussion  
No single optical detection modality is sufficiently accurate to gain clinical 
acceptance as a screening tool for preneoplastic bronchial lesions. Except for 
autofluorescence bronchoscopy, limited patient data on these new techniques are 
available. Autofluorescence bronchoscopy has proven its value in the detection of 
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neoplastic lesions, but unfortunately the low specificity limits this technique to be 
used as a screenings tool. 
Based on the currently available techniques a combination of a wide-field optical 
imaging technique and a point (imaging) technique might improve the detection 
rate. A wide field technique is used to locate several suspicious lesions, and a 
point imaging technique is subsequently used to differentiate between true positive 
or false positive lesions.  
For the first purpose, autofluorescence bronchoscopy seems momentarily the best 
wide field optical technique since a large number of investigations has been 
proven that this technique is with a high sensitivity. 
For the second purpose, OCT combined with DPS have the highest potential 
value. OCT provides a histological-like diagnosis on site based on endogenous 
contrast, which increases the specificity of the fluorescence bronchoscopy during 
bronchoscopy and it is the only non-contact point imaging techniques. The non-
contact possibility prevents contact bleeding and therefore misinterpretations of 
investigated lesions. Furthermore, it is a technique where quantitative data of the 
epithelial thickness can help to draw conclusions about the seriousness of a 
premalignant lesion.  
DPS informs about the superficial morphology and physiology of the bronchial 
tissue, and therefore provides information complementary to OCT images. The 
incorporation of these three techniques includes the three important conditions of 
detection of premalignant lesions. Firstly, a wide field technique for detection of 
suspicious lesions. Secondly, a point imaging technique to give more local 
information about the histology of the suspicious lesions, and thirdly, a 
spectroscopic technique which gives information about the physiology of the local 
tissue.  
 
 
Conclusion 
In conclusion, a combination of autofluorescence bronchoscopy with OCT and 
DPS seems for now the best technique to be used in future studies on 
premalignant lesions. In addition, none of the presented techniques, or a 
combination of techniques, can be advised to be used outside a research setting. 
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Summary  
Tumor hypoxia is generally considered to be related to aggressive behaviour of a 
tumor. As in lung cancer direct determination of oxygenation is difficult, hypoxia-
related proteins have been studied. A number of studies on these proteins show 
different results and the usefulness of these protein expressions remains 
questionable. In this article, we relate one of these hypoxia-related proteins 
(hypoxia-inducible factor, HIF1a) to a direct in vivo spectroscopic measurement of 
tumor blood saturation performed during bronchoscopy. 
Seventeen samples from malignancies and non-malignant tissues were studied. 
Microvascular saturation levels in the no malignancy group equalled 87±11.5% 
(range 71-100%) and in the malignant group 43±21% (range 6-63%). This 
difference was statistically significant (p < 0.0002). There was a significant 
difference in the spectroscopically determined saturations between the biopsies 
with negative expression of HIF1a and the biopsies with positive expression of 
HIF1a (p < 0.005). 
From these data, it can be concluded that HIF1a expression is related to a low 
microvascular blood saturation as determined in vivo by optical spectroscopy. This 
study may lead to a better acceptance of the usage of different techniques to 
establish hypoxia in order to study the effect of hypoxia on therapeutic 
interventions and prognosis of lung cancer. 
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1. Introduction 
Tumor hypoxia has become of increasing interest in several forms of cancer and is 
generally considered to be related to a more aggressive behaviour of a tumor [1-
3]. Tumor hypoxia is also related to a diminished response to radiotherapy and 
chemotherapy [4,5]. In lung cancer, direct determination of the tissue oxygen 
status in vivo was not possible until recently, due to the inaccessibility of the organ 
[1]. For that reason, endogenous hypoxia-related parameters have been 
determined in biopsies ex vivo. One of the most studied hypoxia-related parameter 
is hypoxia-inducible factor 1a (HIF1a) [1,2]. HIF1a is the oxygen-regulated subunit 
of hypoxia-induced factor 1 (HIF1). HIF1a is kept at low levels under normoxic 
conditions due to the continuous degradation via the ubiquitin-dependent 
proteasome pathway. Hypoxia results in an increase in the HIF1a protein levels, 
thereby activating genes involved in tumor metabolism, growth and angiogenesis. 
In recent years, a number of papers have been published relating the expression 
of hypoxia-related proteins like HIF1a to survival in patients with lung cancer [6]. 
Other hypoxia markers, such as CA IX have been studied as well, with 
comparable results [1,7]. However, the use of these endogenous hypoxia markers 
is still not firmly established in lung cancer due to the fact that a direct comparison 
between these hypoxia markers and cellular oxygen tension was not possible. 
We recently developed and validated a new method to measure the microvascular 
saturation real-time and noninvasively by use of optical spectroscopy, that can be 
used during bronchoscopy. In an earlier study, we observed that lung carcinoma 
was associated with lower microvascular saturation than normal and metaplastic 
tissues [8]. 
The aim of the present pilot study was to establish whether a biologic marker for 
hypoxia, HIF1a, is related to the spectroscopically determined microvascular 
saturation. 
 
 
2. Methods 
 
2.1. Patients 
Patients with known or suspected malignancies of the lung and with a medical 
indication for a bronchoscopy were invited to participate. All patients were older 
than 18 years and provided written informed consent. None of these patients were 
included in previous studies. The study was approved by the local Medical Ethics 
Review Board. 
 
2.2. Examination procedure 
The endoscopic examination of the bronchial tree was performed with a 
commercially available flexible fluorescence bronchoscope (Karl Storz® 11004BI, 
Germany). All lesions that appeared abnormal at blue and/or white light imaging 
were measured. The DPS fiber-probe was led through the working channel of the 
bronchoscope and placed in gentle contact with the bronchial mucosa. The 
duration of reflectance spectral acquisition was less than 1 s during which the light 
source of the bronchoscope was switched off. An average of three measurements 
was done on each location. 
Bronchial biopsies of the lesions were obtained at exactly the same place of the 
spectroscopic measurement. First a biopsy for histological examination was 
obtained, then a biopsy was taken for determination of HIF1a expression and 
Chapter 3 
 
56 
afterwards, again a biopsy for histological examination was obtained. The biopsy 
for HIF1a expression was directly snap frozen in liquid nitrogen. For histological 
examination, the biopsies were transported in formaldehyde and fixed in paraffin. 
The pathological diagnoses were coded referring to the World Health Organisation 
Lung Cancer classification. 
 
2.3. Differential path-length spectroscopy 
The DPS technique has been previously described in great detail [8,9]. In short, 
spectra are measured using a custommade instrument using a fiberoptic probe 
small enough to be led through the working channel of a flexible bronchoscope. 
One fiber (delivery-and-collection (dc)-fiber) is used for both delivery and detection 
of light. The second fiber (collection (c)-fiber) is used for only detection of reflected 
light from the tissue. A tungsten-halogen lamp (Ocean Optics HL- 2000-FHSA, 
Duiven, The Netherlands) is used to light up the bronchial mucosa through the dc-
fiber and the remitted light collected in the dc- and c-fiber is analysed in a dual 
channel spectrometer (Ocean Optics, SD2000). The difference of the dc- and c-
fiber collection signals is the differential reflectance signal R(λ). In the range of 
parameters relevant for biological tissue, we have previously reported that the 
differential reflectance signal R(λ) can be modelled by [8]: 
 
 
 
(1) 
 
where C1 is a proportionality constant related to the density of scatterers in the 
tissue, b the so-called Mie parameter related to the size distribution of the 
scattering particles in the tissue [refs.], ρ the blood volume fraction, StO2 the 
microvascular blood oxygenation,  (λ) the absorption coefficient of fully 
oxygenated whole blood,  (λ) the absorption coefficient of fully deoxygenated 
whole blood and Ccor is a correction factor that accounts for the inhomogeneous 
distribution of blood in tissue [10] and is related to the vessel diameter (Dvessel). 
Fitting the data to our equation yields values for the local blood oxygenation 
(StO2), local blood volume fraction (ρ), apparent average vessel diameter (Dvessel) 
and the Mie parameter (b). Since the path length of the photons which have 
travelled through the tissue is short (apparent differential path length = 320 µm), 
the optical properties extracted from the differential reflectance signal characterize 
the most superficial layer of the tissue (roughly within 160 µm of the tissue 
surface). 
 
2.4. Western blot analysis of HIF1a expression 
Frozen biopsies were pressed through a 40 µm mesh cell strainer (BD 
Biosciences, San Jose, CA, USA) using 100 µl of lysis buffer (20mM Tris pH 7.4, 
150mM NaCl, 1mM EDTA, 0.1% NP40 and mini-complete protease inhibitors 
[Roche, Basel, S]). After 30 min incubation in ice, the protein suspension was 
centrifuged for 10 min at 12,000×g at 4 ◦C. The protein concentration was 
determined using 2D Quant (GE Healthcare-Amersham, Buckinghamshire, UK) 
and separated by one-dimensional SDS-PAGE. Proteins were electroblotted onto 
Immobilon P membranes (Millipore Corp, Etten-Leur, The Netherlands) and 
incubated with specific antibodies, followed by horseradish peroxidase-conjugated 
secondary antibodies and detected using SuperSignal West Pico 
HIF1a expression in bronchial biopsies correlates with tumor microvascular saturation determined 
using optical spectroscopy 
57 
chemiluminescent substrate (Pierce Perbio Science, Etten-Leur, The 
Netherlands). Antibodies used in this study were anti- HIF1a (1:250, clone [BD 
transduction laboratories] and anti-beta-tubulin (1:2000, clone E7, Developmental 
Studies Hybridoma Bank, Iowa City, IA, USA) as control. Quantification of the 
expression levels were performed in duplicate by two independent observers 
denoted as negative/weak or positive/strong staining. 
 
2.5. Statistical analysis 
Variance analysis between saturation and negative and positive expression of 
HIF1a were tested using Wilcoxons rank sum test. 
 
 
3. Results 
Nine patients were included in this pilot study and 17 different locations that 
appeared endoscopically abnormal under white light or fluorescence 
bronchoscopy were measured and biopsied. Mean age was 62 years (range 50-90 
years). All patients were analysed because of a suspicion for lung cancer. No 
desaturations during bronchoscopy were established using pulse-oximetry. The 
histology of these samples is denoted in Table 1. 
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In all the subjects, the two biopsies taken for histological examination were 
compared. It was found that these biopsies showed a similar histology. Since the 
biopsy for HIF1a expression was taken in between those two, we are confident 
that the biopsy used for HIF1a expression will have a similar histology. 
Due to the well-known low specificity of fluorescence bronchoscopy, histology 
varied from no dysplasia to invasive cancer. Microvascular blood saturation values 
ranged from 6 to 100%. In this pilot study, the data of non and mild dysplastic 
tissues were combined into a ‘‘no malignancy’’ group and the data of severe 
dysplasia and tumors into a ‘‘malignant’’ group for statistical purposes. 
Microvascular saturation levels in the no malignancy group (n = 11) equalled 
87±11.5% (range 71-100%) and in the malignant group (n=6) 43±21% (range 6-
63%). This difference was statistically significant (p < 0.0002). There was a 
significant difference in the spectroscopically determined saturations between the 
biopsies with negative expression of HIF1a and the biopsies with positive 
expression of HIF1a (p < 0.005; Fig. 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Difference between HIF1a expression level expressed as small amount in case of absent or 
low expression and large amount in case of moderate or high expression in relation to the 
measured saturation 
 
 
4. Discussion 
We studied the relation between an indirect, ex vivo determined measure of 
hypoxia (HIF1a) and a real-time, non-invasive, in vivo measurement of blood 
oxygen saturation using optical spectroscopy. It was found that the expression of 
HIF1a was related to the optically determined microvascular oxygen saturation. 
Determination of hypoxia-related proteins like HIF1a has been subjected to many 
studies in recent years. In contrast to many other tumors, the oxygen status in lung 
cancer cannot be determined directly (for instance with polarographic techniques) 
due to the inaccessibility of the bronchial tree. Only during operation, recently a 
study was published using an Eppendorf polarographic electrode, in which oxygen 
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tension was related to hypoxic markers, one of them being CA IX [11]. In their 
study, tissue oxygen tension correlated with expression of CA IX. In our study, 
patients with more advanced disease are studied which are in general associated 
with a lower oxygen tension. Also, our method is less invasive and can easily be 
done during bronchoscopy, but of course, is dependent on visualisation of the 
tumor during bronchoscopy. 
The method used in this study is based on optical spectroscopy (differential path-
length spectroscopy, DPS) to determine tumor blood-oxygen saturation 
[8,9,12,13]. In earlier studies using this technique, it was shown that malignancies 
were associated with a low microvascular saturation [8]. The determined values of 
microvascular saturation are highly reproducible. It is the subject of ongoing 
research to investigate saturation levels in premalignancies in order to increase 
specificity of fluorescence bronchoscopy. In lung tumors, we are evaluating the 
relation between microvascular saturation levels and survival. Also the relation 
between microvascular saturation levels and efficacy of therapy is the subject of 
study. One could theoretically predict that hypoxic tumors will be more resistant to 
radiotherapy, while the response to chemotherapy may also be related to 
microvascular saturation levels. Presently no data on these subjects are 
published. 
DPS determines the tumors microvascular blood saturation as opposed to the 
tumors tissue oxygen tension as determined with HIF1a, a marker for cellular 
hypoxia. Although microvascular blood saturation and tissue oxygen tension may 
not be similar, they will be related. Certainly, if low blood saturation levels are 
measured, it cannot be expected that tissue oxygen tensions are high. In case of 
high blood saturation levels, however, tissue oxygen levels may still be low due to 
increased oxygen consumption and diffusion capacity problems. 
Tumor hypoxia is becoming of increasing interest since a relation between hypoxia 
and metastases and survival has been described in several studies using hypoxia-
related proteins, as reviewed in Ref. [2]. A higher expression of hypoxia-related 
proteins was shown to be related to a higher rate of metastases and a shorter 
survival. In this excellent review, the relation between hypoxia and tumor 
aggressiveness is discussed in great detail. The conclusions of the studies on 
expression of hypoxia-related proteins are not uniform [1]. In some of the studies, 
the relation between the protein expression and survival was not found, 
questioning the usefulness of these indirect measures of hypoxia [3,7]. As we do 
find a correlation between oxygen tension and the expression of hypoxia-related 
proteins, it is our hypothesis that this inconsistency is related to differences in the 
sampling of tissue for protein expression. Most of the samples studied for protein 
expression are samples from patients who have been operated. In a tumor, the 
tissue saturation will not be the same in the whole tumor [2]. In most of the ex vivo 
studies, it is not known where the sample for protein determination is taken from. 
The center of a tumor may be more hypoxic than its periphery causing high 
expression of hypoxia-related proteins in the center of the tumor, while the 
periphery of the tumor may be characterized by a low expression of hypoxia-
related proteins. 
We hypothesize that the presence of hypoxic areas on the periphery of a tumor 
are better predictors of invasive growth and thus of the rate of metastases than 
hypoxic areas in the centre of the tumor. For instance, squamous cell carcinomas 
are known to have necrotic centres, causing high expression of hypoxia-related 
proteins in the centres of these tumors, while these large necrotic tumors may 
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present without metastases. Interestingly, in a separate study, we found that 
squamous cell carcinomas, presenting with central necrosis were characterized by 
relatively high blood saturation at the periphery of the tumor. The average 
microvascular saturation measured with DPS of squamous cell carcinomas was 
found to be 61% (n = 10), while the average microvascular saturation of all other 
histological types (n = 24) was 43%. 
In conclusion, two independent measures to determine hypoxia in tissue, either by 
ex vivo protein expression or by in vivo optical spectroscopic techniques, show a 
good correlation. The determination of hypoxia may be of importance, for example, 
in the choice of therapeutic agents. In a recent article on the effect of 
tyrapazamine, it was suggested that the absence of a beneficial effect of this agent 
might be related to the percentage of hypoxic cells in a tumor. Furthermore, 
hypoxic tumors may be more resistant to ionizing radiation [2]. 
Our results open the field for in vivo research on hypoxia, e.g. on the effect of 
different therapeutic options like angiogenesis inhibitors, hypoxia targeted agents 
like tyrapazamine or the effects of radiotherapy on hypoxic lung tumors. 
 
 
HIF1a expression in bronchial biopsies correlates with tumor microvascular saturation determined 
using optical spectroscopy 
61 
References 
 
[1] Kim SJ, Rabbani ZN, Dewhirst MW, Vujaskovic Z, Vollmer RT, Schreiber EG, et al. Expression 
of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. Lung 
Cancer 2005;49(3):325—35. 
[2] Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular 
aspects. J Natl Cancer Inst 2001;93(4):266—76. 
[3] Evans SM, Koch CJ. Prognostic significance of tumor oxygenation in humans. Cancer Lett 
2003;195(1):1—16. 
[4] Li L, Yu J, Xing L, Ma K, Zhu H, Guo H, et al. Serial hypoxia imaging with 99mTc-HL91 SPECT 
to predict radiotherapy response in nonsmall cell lung cancer. Am J Clin Oncol 2006;29(6):628—
33. 
[5] Song X, Liu X, Chi W, Liu Y, Wei L, Wang X, et al. Hypoxiainduced resistance to cisplatin and 
doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene. Cancer 
Chemother Pharmacol 2006;58(6):776—84. 
[6] Giatromanolaki A, Koukourakis MI, Sivridis E, Turley H, Talks K, Pezzella F, et al. Relation of 
hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/ 
molecular profile of tumours and survival. Br J Cancer 2001;85(6):881—90. 
[7] Kim SJ, Rabbani ZN, Vollmer RT, Schreiber EG, Oosterwijk E, Dewhirst MW, et al. Carbonic 
anhydrase IX in early-stage non-small cell lung cancer. Clin Cancer Res 2004;10(23): 7925—33. 
[8] Bard MP, Amelink A, Hegt VN, Graveland WJ, Sterenborg HJ, Hoogsteden HC, et al. 
Measurement of hypoxia-related parameters in bronchial mucosa by use of optical spectroscopy. 
Am J Respir Crit Care Med 2005;171(10):1178—84. 
[9] Amelink A, Sterenborg HJ, Bard MP, Burgers SA. In vivo measurement of the local optical 
properties of tissue by use of differential path-length spectroscopy. Opt Lett 2004;29:1087—9. 
[10] van Veen RLP, Verkruysse W, Sterenborg HJCM. Diffusereflectance spectroscopy from 500 to 
1060nm by correction for inhomogeneously distributed absorbers. Opt Lett 2002;27:246—8. 
[11] Le QT, Chen E, Salim A, Cao H, Kong CS, Whyte R, et al. An evaluation of tumor oxygenation 
and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res 
2006;12(5):1507—14. 
[12] Bard MP, Amelink A, Skurichina M, Noordhoek Hegt V, Duin RP, Sterenborg HJ, et al. Optical 
spectroscopy for the classification of malignant lesions of the bronchial tree. Chest 
2006;129(4):995—1001. 
[13] Bard MP, Amelink A, Skurichina M, den Bakker M, Burgers SA, van Meerbeeck JP, et al. 
Improving the specificity of fluorescence bronchoscopy for the analysis of neoplasticlesions of the 
bronchial tree by combination with optical spectroscopy, preliminary communication. Lung Cancer 
2005;47(1): 41—7. 
 

  
Chapter 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
Relation of lung cancer histology to 
peripheral microvascular saturation 
measured by optical spectroscopy 
 
 
C. van der Leest1,2 
A. Amelink3  
M. Bard4 
P. Mulder5  
R. Djamin1 
D. Sterenborg3 
H.C. Hoogsteden2 
J.G.J.V. Aerts1,2 
 
1 Department of Pulmonary Diseases, Amphia Hospital, Breda, The Netherlands 
2 Department of Pulmonary Diseases, Erasmus MC, Rotterdam, The Netherlands 
3 Center for Optical Diagnostics and Therapy, Department of Radiation Oncology, Erasmus MC, Rotterdam, 
The Netherlands 
4 Department of Pulmonary Diseases, Kennemer Gasthuis, Haarlem, The Netherlands 
5 Department of Department of Epidemiology & Biostatistics, Erasmus MC, Rotterdam, The Netherlands 
 
Submitted 
Chapter 4 
64 
Abstract 
Introduction: Lung cancer is historically divided into Non-Small Cell Lung Cancer 
(NSCLC) and Small Cell Lung Cancer (SCLC), due to differences in treatment 
options and prognosis. 
Hypoxia is a well known parameter in many solid tumors and has been related to 
high metastatic rate and poor prognosis. Whether hypoxia is different between the 
histological subtypes of lung cancer is unknown. The aim of the study was to 
compare spectroscopic determined saturation levels of endobronchial NSCLC and 
SCLC tumors and relate this to survival. 
Methods: Differential pathlength spectroscopy (DPS) was used during 
bronchoscopy. Hereby peripheral in vivo microvascular saturation data were 
obtained in different histological subtypes of lung tumors. DPS data were 
correlated with endobronchial tumors histology corrected for stage of disease. 
Results: In 98 patients DPS data could be correlated to histological-confirmed 
endobronchial tumor tissue. No differences in oxygenation between NSCLC and 
SCLC were established. Adenocarcinomas and squamous cell carcinomas had a 
better peripheral oxygenation, StO2 65% (± 20,0) and 58% (± 28,9) respectively, 
compared to large cell carcinoma and SCLC, StO2 42% (± 28,9) and 38% (± 28,2) 
(p <0.05) respectively. No relation between peripheral microvascular tumor 
saturation and survival could be established. 
Conclusion: Although differences in peripheral microvascular saturation, 
measured during bronchoscopy, between the histological subtypes of lung cancer 
can be observed, this is not related to survival.  
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Introduction 
Based on treatment potentials, lung cancer is historically subdivided into two 
subtypes, Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer 
(SCLC)1. Compared to NSCLC, SCLC is in general associated with higher mitotic 
rate and higher metastatic potential1. For this reason, SCLC is considered 
metastasized at diagnosis and surgery is limited to a very selected population of 
patients which are also treated with adjuvant chemotherapy.  
One of the key factors considered to be related to the aggressiveness of a tumor is 
hypoxia2-4. Hypoxia is a well known phenomenon in many solid tumors5. Three 
main reasons cause tumor hypoxia 6. First, inadequate blood flow of tumor tissue. 
Hypoxia can be caused by inadequate vascular network and impaired blood 
vessels resulting in absence of flow regulation or stasis. Second, increased 
diffusion distance. By tumor expansion without increment of microvessel network 
the distance between the oxygen providing vessels and the cells become larger. 
Third, tumor associated anemia can cause reduction in oxygen supply to tumors7-
9
. 
Using reflectance spectroscopy it is possible to determine peripheral 
microvascular saturation of endobronchial tumors during bronchoscopy10. A 
previous study of our group showed lower peripheral microvascular saturation 
levels of endobronchial tumors compared to normal bronchial tissue10 and this 
lower microvascular saturation was correlated with a higher hypoxia inducible 
factor 1-alpha (HIF1a) expression11. 
We studied the microvascular saturation levels of SCLC and NSCLC. Different 
histological subtypes of NSCLC were compared as well. Finally the relation 
between peripheral microvascular saturation and survival was studied.  
 
Material and methods 
Subjects 
In this non-randomized open study, patients with suspect malignancies of the lung 
and therefore medical indication for bronchoscopy were invited to participate. All 
patients were above 18 years old. The study was approved by the Medical Ethics 
Review board of the Erasmus Medical Centre Rotterdam, the Netherlands. 
Survival follow up was performed by status research and contacting the General 
Practitioner. 
 
Histology 
Endobronchial tumors were classified according to the World Health Organization 
(WHO) criteria1, by a dedicated pathologist who was blinded for the DPS results. 
Patients with histology confirmed lung cancer diagnosis were included. Patients 
with cytological confirmation of lung cancer were excluded.  
 
Examination procedures 
Bronchoscopy was performed with a pentax bronchoscope. Any macroscopically 
visible tumor lesions could be measured. The DPS fiber was led through the 
working channel of the bronchoscope and placed in gentle contact with the 
bronchial mucosa. The duration of one spectral measurement was less than one 
second. An average of three spectra was taken in order to take into account the 
heterogeneity of the tissue. After measurement, histology biopsies of the 
measured place were obtained.  
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Differential path length spectroscopy 
The DPS technique has been previously described in great detail10. In short, 
spectra are measured using a custom made fiberoptic probe containing two fibers, 
small enough to be led through the working channel of a flexible bronchoscope. 
One fiber is used for both delivery and detection of light, the other is only used for 
detection of reflected light from the tissue. A Xenon  lamp (Ocean Optics, HPX 
2000) is used to light up the bronchial mucosa through the deliver and detection 
fiber and the remitted light collected in both fibers is analyzed in a dual channel 
spectrometer (Ocean Optics, SD2000). The difference between the two collecting 
signals is the differential reflectance signal. In the range of parameters relevant for 
biological tissue we previously reported that the differential reflectance signal R(λ) 
can be modeled by10 . 
R(λ) = C1λ-b exp{-0.32Ccor (λ) ρ[StO2µaHbO2 (λ) + (1- StO2µaHb (λ)]}, 
where C1 is a proportionality constant, b is a parameter related to the size of the 
scattering particles, Ccor is a correction factor that accounts for the inhomogeneous 
distribution of blood in tissue and its related vessel diameter Dvessel, ρ is the blood 
fraction, STO2 is the microvascular blood oxygenation, µaHbO2 (λ) is the absorption 
coefficient of fully oxygenated whole blood, and µaHb (λ) is the absorption 
coefficient of fully deoxygenated whole blood. 
Fitting the data to our equation yields values for the local blood oxygenation (%) 
and with this technique is it possible to measure direct in vivo saturation of the 
superficial layer of the bronchial mucosa and tumour tissue. 
Since the path length of the photons which have travelled through the tissue is 
short (apparent differential path length = 320µm), the optical properties extracted 
from the differential reflectance signal characterize the most superficial layer of the 
tissue (roughly within 160µm of the tissue surface). 
 
Statistical analysis 
Differences of peripheral microvascular saturation between the histological types 
of cancer were evaluated with univariate analysis adjusted for stadium and 
gender. This was done by SPSS. T-tests between different histology and average 
saturation, adjusted for stadium and gender, were performed. Survival analyses 
were evaluated with the Kaplan Meier curves and a log rank scale. Log Rank test 
was used to asses the best discriminative StO2 in relation to survival. P values 
less than 0.05 were regarded as significant.  
 
Results 
Between January 2004 and April 2008, 98 patients (73 men, 25 women) were 
included. In these patients, with histological biopsies confirmed lung cancer, DPS 
measurements were performed. Patients’ data are shown in table 1. Endoscopic 
determined DPS saturation levels are shown in table 2. Average number of DPS 
measurements per tumor was 3.6 (range 1-10). 
No differences in peripheral tumor microvascular saturation were established 
when NSCLC and SCLC as a group were compared, irrespective of stadium (table 
3 and figure 1). Peripheral microvascular saturation levels were 51.2% (±29) in 
NSCLC and 37.5 (±28.2) in SCLC. The NSCLC group was divided into the three 
subgroups; Adenocarcinomas (ADC), squamous cell carcinomas (SCC) and large 
cell carcinomas (LCC). Comparing these subgroups and SCLC, irrespective of 
stadium, differences of peripheral tumor microvascular saturation were observed. 
ADC and SCC were better oxygenated, StO2 65% and 58% respectively, 
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compared to LCC and SCLC, StO2 42% and 38% respectively (Table 3 and figure 
2). No significant difference between stage I/II compared to III/IV was observed. 
The stage I and II tumors were mainly SCC (66.7%). A subgroup analysis between 
stage I/II SCC and stage III/IV SCC showed no significant results (p-value 0.219). 
The survival data in the SCC group were significant different between stage I/II 
and III/IV (p=0.009). Mean follow up of all the patients was 2.5 (±1.7) year. 
Evaluation of survival data and peripheral tumor microvascular saturation showed 
no significant difference, although the curve was in favor of the tumors with higher 
microvascular saturation (figure 3). Univariate analysis was performed in order to 
exclude confounders. The univariate analyses, including gender and tumor 
stadium, showed no significant difference between the independent variants and 
the relation between peripheral tumor microvascular saturation and histology. 
 
Discussion 
We studied a hypoxia related parameter in relation to the different endoscopic 
visible lung tumors using DPS technology. In addition, we investigated the 
prognostic value of this parameter. It was found that SCLC and LCC are 
associated with the lowest blood oxygenation compared to ADC and SCC. There 
was no correlation between peripheral tumor microvascular saturation and overall 
survival.  
SCLC represents one of the more aggressive types of lung cancer with necrosis 
and high mitotic count1. Rapid cell division rate is associated with increased cell 
metabolism and increased oxygen consumption and when neoangiogenesis flow 
becomes inadequate, blood flow diffusion distance increases, leading to tumor 
hypoxia 7. Based on WHO criteria LCC is considered to be a NSCLC which does 
not fit into the criteria of either squamous or adenocarcinoma. LCC do not have 
clear cut morphological signs of differentiation, considering poorly angiogenetic 
architecture. Tumor bloodvessels with poor angiogenetic architecture become 
leaky and tortuous causing impaired blood flow 12, 13. This impaired blood flow 
causes lower blood saturation. 
Hypoxia is a known prognostic tumormarker in many solid tumors. In lung cancer 
these data are not definite. In our study we do not find peripheral microvascular 
saturation as a prognostic marker. Striking are the high saturation levels of the 
peripheral adeno and squamous cell subtypes. Although the microvascular 
saturation is lower compared to normal bronchial tissue, the microvascular 
saturation is unexpected high. Several other studies support the idea that NSCLC 
is a less hypoxic tumor. A study with the Eppendorf electrode showed a median 
pO2 of 16 mm Hg (range 0.7-46 mm Hg)14. One other hypoxia-related study, using 
a tracer 18F-fluoromisonidazol (18-F-FMISO), found only small areas of hypoxia in 
adeno and squamous cell carcinomas15. They hypothesized that the unique 
structure of the lung parenchyma, including the dual blood supply and the 
abundant oxygen-containing air spaces, might be the reason why some lung tumor 
types are less hypoxic than others.  
The studies which measured lung tumor hypoxia with the Eppendorf 14 and the 18-
F-FMISO 15 support our finding of a high microvascular saturation level in 
endobronchial adeno and squamous cell carcinoma tissue. As DPS measures only 
a small size of the peripheral tumor, we don’t have data about central tumor areas. 
By using 18-F-FMISO all the hypoxic areas are visible including the centre of the 
tumor16. For complete information about tumor hypoxia, 18-FMISO is superior to 
DPS. However, 18-F-FMISO is a technique where the uptake of tracer 18F-
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fluoromisonidazol is qualitative related to hypoxia and spatial resolution is a 
problem. DPS utilized reflectance spectra to provide quantitative hypoxia related 
data. 
Localizing sub-populations with tumor hypoxia which are more resistant to 
radiotherapy and chemotherapy would enable to customize the treatment. Our 
results show that LCC and SCLC are the type of tumors with a lower saturation. 
An early study with tirapazamine, a hypoxic cytotoxin, showed promising results in 
patients with NSCLC17. Tirapazamine is an aromatic heterocycle di-N-oxide, which 
is activated to a toxic radical only at very low levels of oxygen18. A phase III study 
(CATAPULT I) showed a benefit of the combination cisplatin and tirapazamine 
over cisplatin alone. Unfortunately the next study (CATAPULT II) showed no 
benefit of cisplatin and tirapazamine over cisplatin and etoposide18. Both studies 
were done in patients with advanced stage NSCLC. Studies with tirapazamine in 
patients with SCLC have been reported as well. Two studies combined 
tirapazamine with concurrent chemo-radiotherapy treatment in patients with limited 
SCLC and showed promising median survival rates19, 20. Our low levels of 
peripheral microvascular saturation in SCLC support their positive study results.    
Peripheral tumor microvascular saturation was not an independent prognostic 
marker in our study. This might be caused by the heterogeneous population. The 
patient population comprises all tumor stadia and therefore all treatment 
modalities. Patients were treated with either surgery, chemo-radiotherapy 
(concurrent or sequential), chemotherapy alone or best supportive care. Diversity 
in stadia and treatment has major influence on the prognosis. It was not possible 
to create a more homogeneous group, because the bronchoscopy including DPS 
measurements were performed in the beginning of the tumor work-up. Therefore, 
no information about histology diagnosis, stage of disease and treatment were 
available before including patients. The patient population is too small to perform 
sub-analysis for prognosis. Future study of a larger study population with a 
homogeneous treatment is necessary for more information about the prognostic 
value of peripheral microvascular saturation. 
No differences in peripheral microvascular saturation between the different tumor 
stadia have been observed. One of the reasons for this is a limited number of 
stage I and II tumors. Secondly, most of the stage I and II tumors are SCC. This 
histological subtype is more often located in the central airways and therefore 
more often visible by bronchoscopy. There was no significant difference in 
microvascular saturation between squamous cell tumors of stadium I/II and 
stadium III/IV. Although the number of patients in this subanalysis is very limited, 
as survival was significant in the two groups, it supports the hypothesis that 
peripheral microvascular tumor saturation is not related to invasiveness of the 
tumor, and therefore not related to prognosis. 
In conclusion, peripheral microvascular saturation measured in endobronchial 
tumors using DPS do not differ between NSCLC and SCLC. ADC and SCC 
contained higher peripheral microvascular saturation compared to LCC and SCLC. 
Peripheral microvascular saturation seems to be related to histological cell 
subtypes and is not prognostic in this analysis. Future studies should take into 
consideration the differences in peripheral tumor microvascular saturation in the 
different histological subtypes of lung cancer to investigate its impact on different 
treatments.  
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SCLC
ADC SCC LCC total
number of patients 12 29 37 78 20
Mean Sat (%) (SD) 64.8 ± 20.0 57.9 ± 28.9 41.6 ± 28.9  51.2 ± 29.0 37.5 ± 28.2  
Median Sat (%) 71.7 57.8 41.3 54.9 35.2
NSCLC
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: patients’ characteristics 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Endoscopic determined DPS saturation levels 
SCLC Total
ADC SCC LCC total
number of patients 12 29 37 78 20 98
Men 7 24 30 61 12 73
Women 5 5 7 17 8 25
Mean Age (years) 64.7 ± 10.9 69.0 ± 8.0 70.9 ± 10.3 69.2 ± 9.7 64.2 ± 10.9
Smoking history 10 29 36 75 20 95
Stage I - 6 2 8 1 9
Stage II - 2 1 3 - 3
Stage III 3 15 19 37 7 44
Stage VI 9 5 15 29 12 41
Unknown - 1 - 1 - 1
NSCLC
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histology microvascular saturation 
p-value
NSCLC versus SCLC 0.158
ADC versus SCC 0.161
ADC versus LCC 0.002*
ADC versus SCLC 0.005*
SCC versus LCC 0.035*
SCC versus SCLC 0.095
LCC versus SCLC 0.928
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3: t-test adjusted for stadium and gender  
Abbreviations: NSCLC total group of non-small cell carcinomas, ADC adenocarcinoma, SCC 
squamous cell carcinoma, LCC large cell carcinoma, SCLC small cell carcinoma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Mean and 95% confidence interval in peripheral saturation between NSCLC and SCLC 
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Figure 2: Mean and 95% confidence interval in peripheral saturation between the different 
histological lung tumors. Abbreviation: adenocarcinoma (ADC), squamous cell carcinoma (SCC), 
Large cell carcinoma (LCC), Small cell carcinoma (SCLC) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Kaplan Meier of survival between the different peripheral tumor saturation 
Chapter 4 
 
72 
References  
 
1. W.D Travis EB, H.K. Muller-Hermelink, C.C Harris. Pathology and genetics of Tumours of 
the Lung, Pleura, Thymus and Heart; 2004; 9-124. 
2. Brahimi-Horn C, Pouyssegur J. The role of the hypoxia-inducible factor in tumor 
metabolism growth and invasion. Bull Cancer 2006;93:E73-80. 
3. Gort EH, Groot AJ, van der Wall E, van Diest PJ, Vooijs MA. Hypoxic regulation of 
metastasis via hypoxia-inducible factors. Curr Mol Med 2008;8:60-7. 
4. Goudar RK, Vlahovic G. Hypoxia, angiogenesis, and lung cancer. Curr Oncol Rep 
2008;10:277-82. 
5. Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev 
Cancer 2008;8:967-75. 
6. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and 
cellular response. Oncologist 2004;9 Suppl 5:4-9. 
7. Hockel M, Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and 
molecular aspects. J Natl Cancer Inst 2001;93:266-76. 
8. Vaupel P, Thews O, Hoeckel M. Treatment resistance of solid tumors: role of hypoxia and 
anemia. Med Oncol 2001;18:243-59. 
9. Vaupel P, Kelleher DK, Hockel M. Oxygen status of malignant tumors: pathogenesis of 
hypoxia and significance for tumor therapy. Semin Oncol 2001;28:29-35. 
10. Bard MP, Amelink A, Hegt VN, et al. Measurement of hypoxia-related parameters in 
bronchial mucosa by use of optical spectroscopy. Am J Respir Crit Care Med 
2005;171:1178-84. 
11. Aerts JG, Amelink A, van der Leest C, et al. HIF1a expression in bronchial biopsies 
correlates with tumor microvascular saturation determined using optical spectroscopy. 
Lung Cancer 2007;57:317-21. 
12. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for 
combination therapy. Nat Med 2001;7:987-9. 
13. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic 
therapy. Science 2005;307:58-62. 
14. Le QT, Chen E, Salim A, et al. An evaluation of tumor oxygenation and gene expression in 
patients with early stage non-small cell lung cancers. Clin Cancer Res 2006;12:1507-14. 
15. Cherk MH, Foo SS, Poon AM, et al. Lack of correlation of hypoxic cell fraction and 
angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-
Fluoromisonidazole and 18F-FDG PET. J Nucl Med 2006;47:1921-6. 
16. Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med 2008;49 Suppl 
2:129S-48S. 
17. Weitman S, Mangold G, Marty J, et al. Evidence of enhanced in vivo activity using 
tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung 
cancer xenograft. Cancer Chemother Pharmacol 1999;43:402-8. 
18. Reddy SB, Williamson SK. Tirapazamine: a novel agent targeting hypoxic tumor cells. 
Expert Opin Investig Drugs 2009;18:77-87. 
19. Le QT, Moon J, Redman M, et al. Phase II study of tirapazamine, cisplatin, and etoposide 
and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222. 
J Clin Oncol 2009;27:3014-9. 
20. Le QT, McCoy J, Williamson S, et al. Phase I study of tirapazamine plus cisplatin/etoposide 
and concurrent thoracic radiotherapy in limited-stage small cell lung cancer (S0004): a 
Southwest Oncology Group study. Clin Cancer Res 2004;10:5418-24. 
 
 
 
 
  

  
Chapter 5 
 
 
 
 
 
 
 
 
 
 
 
 
Integration of single fiber reflectance 
spectroscopy into ultrasound-guided 
endoscopic lung cancer staging of 
mediastinal lymph nodes 
 
S.C. Kanick1 
C. van der Leest 2,3 
J.G.J.V. Aerts2,3 
H.C. Hoogsteden2 
Slávka Kaščáková1 
H.J.C.M. Sterenborg1 
A. Amelink1 
 
1 Center for Optical Diagnostics and Therapy, Department of Radiation Oncology,  Erasmus MC, Rotterdam, 
The Netherlands  
2 Department of Pulmonary Diseases, Erasmus MC, Rotterdam, The Netherlands 
3 Department of Pulmonary Diseases, Amphia Hospital, Breda, The Netherlands 
 
 
Journal of Biomedical Optics 15 (1), Januari/Februari 2010 
 
Chapter 5 
 
76 
Integration of single fiber reflectance spectroscopy into ultrasound-guided endoscopic lung cancer 
staging of mediastinal lymph nodes 
77 
Chapter 5 
 
78 
Integration of single fiber reflectance spectroscopy into ultrasound-guided endoscopic lung cancer 
staging of mediastinal lymph nodes 
79 
Chapter 5 
 
80 
Integration of single fiber reflectance spectroscopy into ultrasound-guided endoscopic lung cancer 
staging of mediastinal lymph nodes 
81 
 
Chapter 5 
 
82 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Integration of single fiber reflectance spectroscopy into ultrasound-guided endoscopic lung cancer 
staging of mediastinal lymph nodes 
83 
 
 
 
 
 
 
 
 
 
 

  
Chapter 6 
 
 
 
 
 
 
 
 
 
 
 
 
Characterization of mediastinal lymph node 
physiology in vivo by optical spectroscopy 
during endoscopic ultrasound-guided fine-
needle aspiration 
 
C. van der Leest1,2  
S.C. Kanick3  
R.S. Djamin1  
A.M. Janssens1  
H.C. Hoogsteden2  
H.J.C.M. Sterenborg3  
A. Amelink3  
J.G.J.V. Aerts1,2 
 
1 Department of Pulmonary Diseases, Amphia Hospital, Breda, The Netherlands 
2 Department of Pulmonary Diseases, Erasmus MC, Rotterdam, The Netherlands 
3 Center for Optical Diagnostics and Therapy, Department of Radiation Oncology,  Erasmus MC, Rotterdam, 
The Netherlands  
 
Journal of Thoracic Oncology in press 
Chapter 6 
 
86 
Abstract 
 
Introduction: Esophageal endoscopic ultrasound guided fine needle aspiration 
(EUS-FNA) is a minimally-invasive staging procedure for mediastinal lymph nodes 
in patients diagnosed with lung cancer.  But, a substantial false negative rate 
necessitates that patients returning a negative EUS-FNA result must undergo a 
subsequent surgical staging procedure. This study incorporates a fiberoptic 
reflectance spectroscopy device into the EUS-FNA procedure to asses the 
vascular physiology within the sampled lymph node. The aim of this pilot study 
was to determine the feasibility of incorporating a reflectance spectroscopy device 
into the EUS-FNA clinical procedure and to gather preliminary information about 
the vascular physiology within the center of normal and metastatic lymph nodes.   
Methods: This study included 10 patients with proven or suspected lung cancer 
and an indication for EUS-FNA.  The procedure was performed on seven normal 
(unenlarged, positron emission tomography negative) nodes and seven suspicious 
(enlarged, positron emission tomography positive), with the malignant status of all 
nodes cytologically confirmed.  Reflectance spectra were acquired using a single 
optical fiber that fits through the end of the EUS-FNA biopsy needle, with an outer 
fiber diameter of 0.38 mm.   
Results: The procedure was successfully performed and did not introduce 
complications.  Model-based analysis of single fiber reflectance spectra provided 
quantitative information about the vascular physiology within the sampled lymph 
node.  We observed that metastatic lymph nodes were characterized by lower 
microvascular oxygen saturation (50% versus 84%, p<0.01) and lower blood 
volume fraction (5.6% versus 13.5%, p<0.01) than normal nodes.     
Conclusions: Single fiber reflectance spectroscopy has the potential to detect 
abnormal lymph node physiology.   
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Introduction 
For patients diagnosed with lung cancer, treatment options are dependent on the 
presence of metastatic cancer in the mediastinal lymph nodes [1].  In the absence 
of clearly identifiable distant metastases, imaging modalities such as Computer 
Tomography (CT) and Positron Emission Tomography (PET) are used to identify 
suspicious nodes (based on size and metabolic activity); however, the sensitivity 
and specificity of these techniques are not sufficient to properly diagnose the 
presence of metastatic cancer, and tissue acquisition from an enlarged lymph 
node is needed for definitive confirmation [2-3].  The gold standard procedure for 
mediastinal staging is an invasive surgical biopsy of the lymph node, termed 
mediastinoscopy [4,5].  An alternative staging approach uses endoscopic 
ultrasound techniques, that are introduced through the esophagus or through the 
bronchial tree [6]. These techniques provide echo visualization of lymph nodes 
and allow incorporation of fine-needle aspirations (FNA) for minimally-invasive 
tissue acquisition.  For staging of mediastinal lymph nodes, the EUS-FNA 
(endocopic ultrasound-guided FNA) procedure is considered less-invasive, less-
expensive, and less-likely to introduce complications than surgical staging 
procedures [6-12].  However, EUS-FNA has a large false negative (FN) rate (~17-
22 %) compared with mediastinoscopy [4,5,7-12]; a substantial limitation that is 
attributed to localized malignant areas within the node that were not sampled 
during EUS-FNA tissue acquisition.  The EUS-FNA FN rate is not reduced 
substantially by increasing the number of aspirations from the current standard 
(reasonable accuracy is obtained after approximately 3 [13]), and the inclusion of 
on-site cytopathology may not improve sensitivity [9] but also introduces additional 
practical and economic considerations. Because of the substantial EUS-FNA FN 
rate, the clinical guidelines recommend that patients receiving a negative cytology 
result from EUS-FNA biopsy of suspicious nodes must undergo a subsequent 
surgical staging procedure for definitive confirmation of the diagnosis [4,5]: a 
procedure that is (retrospectively) unnecessary in approximately 77-81% of 
patients, because the negative EUS-FNA result was indeed correct.  
Hypothetically, a method that provided additional, complementary information 
about the malignant status of lymph nodes could improve EUS-FNA FN rate, 
reducing unnecessary spending of resources and avoiding unnecessary delay 
before the onset of treatment administration.    
Previous studies investigating the physiology of lymph node metastases have 
observed systematic effects of the metastatic sites on the vasculature within the 
node [14-18].  These studies observed the presence of aberrant vessels, 
displacement of vessels, and avascular areas in the center of the node, with the 
primary source of perfusion from the peripheral vasculature.  Such observations 
indicate a compromised vascular network within the center of the node, changes 
that would affect local tissue blood content and blood oxygen saturation.  These 
physiological changes provide a hypothetical basis to differentiate between normal 
and metastatic lymph nodes; specifically, these physiological aspects 
(microvascular saturation and blood content) can be measured by fiber-optic 
reflectance spectroscopy.  This pilot study aims to incorporate a fiber-optic 
measurement technique into the EUS-FNA procedure that would return unique 
quantitative information about node vascular physiology, information that would be 
complementary to the cytological observations, and potentially improve the EUS-
FNA FN rate.   
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Reflectance spectroscopy in the visible-near infrared wavelength region provides 
information about the wavelength dependent optical properties that allow 
estimation of tissue physiological parameters [19].  The dominant absorption 
bands of hemoglobin in the visible wavelength region allow both the blood content 
and hemoglobin saturation to be estimated from the reflectance measurement.  
Previously, our group developed differential path length spectroscopy (DPS) to 
quantitatively determine tissue physiological characteristics [20]. DPS utilizes a 
unique probe geometry that provides knowledge of the photon path length [21] and 
allows accurate description of optical properties in small volumes of tissue; the 
accuracy of this technique has been extensively validated [22] and clinically 
investigated [23-27].  However, DPS probes include multiple optical fibers and are 
too large to be incorporated into the biopsy needle at the end of the EUS-FNA 
catheter (which has an internal diameter of ~0.45 mm).  This clinical application 
requires the use of a fiber optic probe with an outer fiber diameter (<0.4 mm) that 
could be incorporated into the narrow channel of the EUS-FNA device.  Our group 
has addressed this problem by developing a novel quantitative analysis technique 
for reflectance spectra measured by a probe that uses a single optical fiber to 
deliver and collect light during the measurement [28-29]; these studies presented 
a mathematical model of the single fiber (SF) photon path length that is accurate 
over a wide range of optical properties and allows quantitative analysis of SF 
reflectance spectra.  Recently [30], we described the detailed technical aspects 
associated with incorporating SF reflectance probes into the EUS-FNA procedure 
for mediastinal lymph node staging: aspects that included the characterization of 
the chromophores (absorbing compounds) present within lymph node tissue, the 
development of a mathematical model of SF reflectance spectra measured within 
the lymph node in vivo, and a detailed analysis of the effects of probe pressure on 
the measured spectra.  In this work we describe the clinical aspects of a pilot study 
that incorporated SF reflectance spectroscopy into EUS-FNA staging of 
mediastinal lymph nodes and present a novel optical sampling strategy that 
addresses the sampling error associated with the current EUS-FNA biopsy 
technique.  The specific aims of this pilot study are to show the feasibility of 
conducting the technique in a clinical setting and to gather preliminary information 
about the vascular physiology within the center of normal (non-suspicious) and 
metastatic (suspicious) lymph nodes in patients undergoing EUS-FNA.   
 
 
Methods 
Subjects 
The Medical Ethics Committee of the Erasmus Medical Centre (Rotterdam, The 
Netherlands) approved this observational study.  Patients were recruited from the 
Erasmus Medical Centre and from the Amphia Hospital (Breda, The Netherlands) 
between December 2008 and April 2009.  Patients who had an indication for an 
EUS-FNA procedure (i.e. presented enlarged lymph nodes on CT scan, or positive 
lymph nodes on a PET scan, or had a primary tumor or had an enlarged left 
adrenal gland that was reachable by EUS-FNA) were asked to participate.  
According to published guidelines for mediastinal staging [4,5], all reachable 
nodes were sampled with FNA to optimally stage the mediastinum; not all FNA 
sampled lymph nodes were measured by reflectance spectroscopy. Written 
informed consent to perform the procedure was obtained from all patients before 
inclusion. 
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Classification of Lymph Nodes 
In this study both unenlarged non-suspicious (normal) lymph nodes and enlarged 
suspicious lymph nodes containing metastatic cancer were included (throughout 
this article lymph nodes containing metastatic cancer are referred to as 
metastatic). Suspicious lymph nodes were defined as visible on CT-scan with a 
short-axis diameter of more than 10 mm and were PET positive.  
Non-suspicious (normal) lymph nodes were defined as PET negative with a short-
axis diameter of less than 10 mm.  This pilot study included only nodes with a very 
defined clinical suspicion for a diagnosis and, therefore, excluded PET negative 
lymph nodes with short-axis diameter of more than 10 mm. The classification of 
each node was confirmed by cytology. Normal nodes were observed during 
minimal 6-month follow-up examinations (except in one who underwent surgical 
staging) to confirm no suspicious enlargement of the node had occurred. 
 
Single Fiber Reflectance Device 
SF reflectance spectra were measured using a custom-made instrument shown in 
Figure 1. The SF probe contained a single optical fiber for both light delivery and 
light collection and was small enough (outer diameter of 0.38 mm) to be fed 
through the biopsy needle channel of the EUS-FNA.  The proximal end of the SF 
probe connects to a bifurcated fiber, with one arm leading to a tungsten-halogen 
lamp (HL-2000-FHSA; Ocean Optics; Duiven, The Netherlands) and the other arm 
leading to a spectrophotometer (SD 2000; Ocean Optics).  The distal end of the 
SF probe, which is in contact with the tissue during measurement, is polished at 
an angle of 15 degree to minimize the collection of specular reflection that is 
caused by refractive index mismatch between the fiber and tissue.  During 
measurement, light in the visible near infrared wavelength range (400-900 nm) 
travels from the lamp to the SF probe tip, exits the fiber and scatters throughout 
the tissue.  Light that is remitted from the tissue and is collected by the fiber 
returns a wavelength-dependent reflectance intensity ( SFR ).  A calibration 
procedure was described previously [28] to account for internal reflections and for 
variability in lamp-specific output and in fiber-specific transmission characteristics.   
 
Examination procedure 
EUS-FNA procedures were performed in an outpatient setting with monitoring of 
heart rate and oxygen saturation.  Lidocain gel was orally administered (10 mL) 
before the EUS-FNA procedure to provide local throat and esophageal anesthesia.  
The patient was oriented into left lateral decubitus and midazolam was 
intravenously administered (2.5-5.0 mg) for mild sedation before introduction of the 
endoscope (Olympus GF-UCT160-OL5).  On placement of the endoscope within 
the esophagus in proximity to the targeted lymph node, a sterile single-use needle 
(Cook Echo-1-22) was introduced through the esophagus and into the lymph node 
using echo guidance.  After needle placement, the guide wire was removed from 
the needle channel, and a sterilized single-use SF probe was introduced into the 
FNA channel.  The fiber optic probe was extended approximately 3 mm through 
the EUS-FNA needle into the center of the lymph node and allowed to rest with no 
external pressure applied to the probe during spectral acquisition.  Manipulation of 
the probe to different locations within the node during measurement can exert 
pressure-induced changes to the endogenous physiology within the node [30]; a 
confounding factor that is avoided using the current sampling strategy of a limited 
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number of SF measurement sites near the center of the node.  Multiple spectral 
acquisitions were performed with a specified minimum of 3 measurements and 
additional measurements obtained based on the judgment of the clinician 
conducting the procedure (range: 3-11, average 7).  After reflectance 
measurements, the fiber optic probe was removed and the routine FNA performed 
to obtain cytologic aspirations.  In this study, 1 to 2 lymph nodes per patient were 
measured with SF reflectance spectroscopy during each EUS-FNA procedure; a 
new FNA needle and a new fiber optic probe were used for each node sampled to 
avoid blood and tissue contamination between nodes.  On average, each EUS-
FNA procedure lasted 30 minutes.  After the procedure, patients were observed 
for 1 hour and then visited by the endoscopist to reveal any side-effects.  Three 
days after the procedure, all patients were returned for an outpatient visit to 
receive test results and to reveal any further side-effects.   
 
Mathematical Analysis of Spectra 
SF reflectance spectra ( SFR ) were analyzed using a previously developed [27] 
mathematical model that describes the wavelength-dependent effects of scattering 
and absorption on the reflectance intensity collected by the SF device in lymph 
node tissue. The model is given as:  
 
 
     
                                                                                                                               
(1)   
 
Here, the term in square brackets is a background scattering model that follows 
Mie theory dependence, with fitted parameters describing the Mie amplitude (a1) 
and Mie slope (a2); Rayleigh scattering was shown to not contribute to SFR  
measured in lymph node tissue [30].   
The model describes attenuation because of absorption through the modified 
Beer-Lambert law that includes the product of the absorption coefficient within the 
lymph node tissue ( tissueaµ ) and the SF photon path length ( SFL ).  Our previous 
study [30], described the basis set of chromophores within lymph tissue as 
oxygenated and deoxygenated hemoglobin (HbO2 and Hb, respectively) and 
albumin-bound bilirubin.  The summed contribution of each of these components 
to tissueaµ is given as follows 
 
                           ( )[ ] bilirubinbilirubinaHbaHbOavtissuea CStOStOC µµµρµ +−+= )1( 222      
  
 (2) 
 
Here ρ is the blood volume fraction, StO2 is the microvascular saturation,  2HbOaµ  is 
the specific absorption coefficient of oxygenated hemoglobin, Hbaµ is the specific 
absorption coefficient of deoxygenated hemoglobin, and bilirubinaµ  and bilirubinC  are the 
specific absorption coefficient and concentration of albumin-bound bilirubin, 
respectively.  Within tissue, whole blood (and in turn Hb and HbO2) is located 
within the vasculature.  This heterogeneous distribution affects the spectral shape 
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of the absorption detected by reflectance spectroscopy: an effect that is 
characterized by the vC  term [31], which is given as, ( ){ } { }vbloodavbloodav DDC µµ /exp1−= , and includes an estimate of the average vessel 
diameter ( vD ).  Application of the Beer-Lambert law in Equation (1) requires 
knowledge of SFL , a factor that is complicated by the dependence of the 
collected photon paths on both the absorption and scattering properties within the 
optically sampled tissue volume.  Recently [28,29], our group developed an 
empirical model that accurately describes SFL  in terms of the SF diameter 
( fiberd ), reduced scattering coefficient ( sµ′ ), and absorption coefficient ( aµ′  ), and is 
given as follows 
 
( ) ( ) 61.018.0 .61.0
54.1
afibersfiber
fiber
SF dd
d
L
µµ +′
=    
  
 (3) 
 
Fitting the measured SFR  data with the model given in Equation (1) yielded 
estimates for the microvascular saturation (StO2), blood volume fraction ( ρ ), 
average vessel diameter ( vD ), bilirubin concentration ( bilC ), and Mie slope ( 2a ); 
the scattering amplitude ( 1a ) did not provide unique information because of 
differences in calibration procedure between probes [30].   
 
Statistical Analysis 
The difference of SF-estimated physiological parameters between normal and 
metastatic lymph nodes was evaluated with a Kruskal-Wallis test.  This non-
parametric test was selected because of the small number of data points.  The 
values of P less then 0.05 were regarded as significant. Spectra that showed 
evidence of a blood pool within the detection volume were identified as ρ more 
than 40% and not included in the statistical analysis.   
 
 
Results 
Lymph Node Staging 
Ten patients were included (six men and four women) with an average age of 68 
(±11.8) years.  Spectroscopic measurements took place in 14 lymph nodes that 
were classified before the EUS-FNA based on CT and PET scans and 
subsequently confirmed through cytology (seven normal and seven metastatic). 
Cytologic conclusions of the metastatic lymph nodes were two adenocarcinomas, 
one undifferentiated large cell carcinoma (large cell), and four small cell 
carcinomas. Table 1 includes a detailed breakdown of patient-specific factors for 
each sampled lymph node.   
Tolerance of the EUS-FNA with combined SF measurements was excellent in all 
patients, and no adverse events of the spectroscopy procedure were observed; 
addition of SF measurements extended no procedure by longer than 5 minutes.  
During the procedure, reflectance spectra and extracted physiological parameter 
estimates were visible less than 1 second after each measurement, information 
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that would immediately indicate if the probe tip was located in a blood pool, 
necessitating repositioning of the probe and measurement of additional spectra.  
This was the case in two normal nodes and one metastatic node.  
 
Single Fiber Reflectance Spectra 
Figure 2 displays representative SF reflectance spectra collected from 
measurements of a metastatic (top) and a normal (bottom) lymph node, both from 
a single patient (patient 9, nodes 12 and 13 from Table 1).  The plots show 
measured data points and the line represents the model fit from Equation (1).  The 
absorption bands of hemoglobin are visible in the spectra as the dips between 500 
and 600 nm; the magnitude and shape of these spectral features inform model 
estimates of blood volume fraction ( ρ ) and microvascular saturation (StO2).  Table 
1 includes a summary of ρ and StO2 estimates for each lymph node sampled by 
SF, with SDs calculated from multiple spectra measured within each node.   
Inspection of these data show that metastatic lymph nodes are associated with 
lower StO2 (50% versus 84%) and lower ρ  (5.6% versus 13.5%) than normal 
nodes; comparison of the mean values of these parameters between normal and 
metastatic nodes indicates significant differences (p<0.01 for each).  Although 
other optical parameters (specifically, vD , bilC and 2a ) extracted from SF spectra 
showed differences in the mean between normal and metastatic nodes, these 
differences were not significant and are not presented in detail in this paper. 
 
 
Discussion 
This work presents the first clinical pilot study incorporating SF reflectance 
spectroscopy into the EUS-FNA procedure for staging of mediastinal lymph nodes.  
The incorporation of the SF technique was feasible, quickly performed in the 
clinical setting, and did not introduce complications or extend the procedure by 
more than 5 minutes.  SF reflectance spectra provided quantitative information 
about the tissue physiology within the lymph nodes. We observed differences in 
the mean values of the model estimates of microvascular saturation and blood 
volume fraction between normal and malignant nodes, with metastatic lymph 
nodes characterized by a lower blood volume fraction and lower microvascular 
saturation: observations that are associated with a compromised vascular supply.  
Previous studies have described the disruptive effect that metastatic cancer within 
lymph nodes has the vascular supply and perfusion within the node. During the 
development of metastatic sites within lymph nodes, malignant cells invade the 
node through the afferent lymphatic vessels and then enter the subscapular sinus 
and cortex of the node, an infiltration route that usually results in metastatic sites 
located in the peripheral areas of the node [15,32]. As these metastatic sites 
proliferate and locally upregulate angiogenesis, they increase the vascularity in the 
peripheral areas of the node [14,15,33,34]. These morphological changes exert a 
mechanical (hydrostatic) pressure on the center of the node, compromising the 
central blood supply. Larger metastases destroy or displace the regular vascular 
network throughout the centre of the lymph node, a feature that can be 
exacerbated by central necrosis or keratinization within the node [16,17]. It is not 
well known if these changes are tumor-type specific or if these changes are 
representative of metastatic infiltration from all tumortypes. Previous studies using 
Doppler techniques reported abnormal vascular characteristics of metastatic 
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nodes, including the presence of aberrant vessels, displacement of vessels, and 
avascular areas, with the primary source of perfusion from the peripheral 
vasculature [14,16-18,33,34].  Our fiberoptic measurements estimated a reduction 
in blood volume fraction and microvascular saturation in the center of metastatic 
nodes as compared with normal nodes, observations that are consistent with the 
previous descriptions in the literature of vascular physiology within metastatic 
lymph nodes. These observations support the concept that reflectance 
spectroscopy can detect abnormal vascular physiology associated with metastatic 
lymph nodes. 
For EUS-FNA staging of lung cancer patients, the clinically relevant problem is the 
classification of suspicious nodes as either reactive (benign) or metastatic. Lymph 
nodes undergoing a reactive immune response may appear suspiciously enlarged 
on CT and/or show increased activity on PET [35]. These reactive nodes are 
known to present vessel dilation and hypervascularity with the highest perfusion in 
the center of the node and proportionality between perfusion and volume of the 
enlarged nodes [36]: factors that would result in an increase in blood volume 
fraction while maintaining a high microvascular saturation within the node.  
Doppler techniques have been used to qualitatively observe and distinguish 
between increased perfusion within reactive nodes [36,37] and decreased 
perfusion within the center of metastatic nodes [14,33,34]; such differences in the 
vascular networks are expected to translate into differences in physiology that are 
quantitable by SF reflectance measurements.  Moreover, these findings suggest 
that differences in vascular characteristics between reactive and metastatic nodes 
are more pronounced than what was observed between normal and metastatic 
nodes in this study. These factors suggest that only a limited number of SF 
reflectance measurements made near the center of a node would be required to 
quantify the regional effect of metastatic disease (or the regional effect of benign 
infection) on the node physiology.  Such a fiberoptic sampling strategy specifically 
would not require optical sampling of localized malignant areas within a node and, 
therefore, would directly address the sampling error associated with the current 
EUS-FNA biopsy technique. It is important to note that whereas the tumorload 
required to change node physiology is currently unknown, but the nodes 
undergoing sampling within this scheme (will) have appeared enlarged on imaging 
scans (or are PET positive) and, therefore, if the tumorload is responsible for node 
enlargement or enhanced metabolic activity, it is reasonable to assume that the 
node physiology has been altered accordingly.  Nevertheless, the sensitivity of the 
SF reflectance measurement to changes in vascular physiology associated with 
the size of the tumorload within metastatic nodes should be carefully investigated 
in an expanded clinically relevant data set.  
Although the preliminary data presented in this study are promising, this pilot study 
is limited in scope and requires further clinical investigation. This pilot study 
included a restricted patient population, with reflectance measurements aquired 
only from nodes with a very defined clinical suspicion for a diagnosis, normal 
(unenlarged, PET negative) and metastatic (enlarged, PET positive), while 
excluding small suspicious nodes (unenlarged, PET positive). This population was 
selected to gather preliminary insight into the vascular physiology associated with 
the limiting normal/metastatic cases, and moreover, this strategy avoided the 
inclusion of nodes enlarged because of immune reaction into the normal 
designation used in this study. Future work will involve a clinical investigation 
within a large population of patients presenting suspicious nodes investigated by 
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EUS-FNA. Another limitation of this pilot study was the determination of normal 
nodes without surgical staging procedures to confirm the absence of metastases.  
Instead, this study confirmed normal nodes using cytologic analysis of aspirate 
acquired during EUS-FNA and conducing subsequent follow-up examinations to 
confirm that nodes identified as normal did not increase in size.  This methodology 
can not conclusively rule out the inclusion of a false negative within the presented 
set of normal nodes. Further investigation is required to make concrete 
conclusions about the clinical utility of the vascular information extracted from 
reflectance measurements of lymph nodes.   
In conclusion, SF reflectance spectroscopy allows real-time analysis of the 
vascular physiology in lymph nodes undergoing EUS-FNA staging procedures.  
Incorporation of the SF technique into the EUS-FNA was well-tolerated, and 
simple to use, and the measured spectra provided unique quantitative information 
about lymph node vasculature.  The SF reflectance technique has the potential to 
improve the quantitative understanding of vascular physiology within lymph nodes, 
understanding this factor till date has been based on qualitative Doppler 
techniques. The data presented in this study demonstrate the feasibility and 
potential utility of SF measurements of vascular changes associated with the 
presence of metastases within lymph nodes.  Moreover, the results obtained within 
this pilot study support the rationale for a novel fiberoptic sampling strategy during 
EUS-FNA, which involves the detection of regional effects of metastatic sites on 
lymph node physiology: a sampling strategy that would not require direct optical 
sampling of metastatic sites within nodes. In addition, the SF technology is 
extensible to any accessible lymph node and may provide information about nodal 
vascular physiology during staging of mediastinal and hilar lymph nodes through 
the bronchial tree.  
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Patient Node Gen Age Site Diam (mm) PET Class Cytology EUS use 
StO2 (%) 
Mean|Stdev 
ρ (%) 
Mean|Stdev 
1 1 F 48 LN 7 40-20 pos M adeno staging 10.8 5.0 1.6 0.5 
2 2 M 53 LN 7 15-0.8 neg N normal staging 81.1 4.4 16.4 6.2 
 3 M 53 LN 4 L 0.4-0.4 neg N normal staging 79.3 0.8 15.3 1.4 
 
3 4 M 82 LN 7 13-0.5 neg N normal staging 91.4 0.6 8.4 1.9 
 5 M 82 LN 4 L 30-20 pos M large cell staging 47.4 22.7 0.12 0.03 
 
4 6 F 82 LN 5 0.7-2.3 pos M adeno staging 48.8 11.4 1.9 1.0 
 
5 7 F 72 LN 4 L 1.4-1.8 pos M SCLC staging 34.2 14.1 5.8 1.9 
6 8 M 63 LN 7 2.9-1.7 pos M SCLC staging 54.9 19.9 5.9 1.7 
 
7 10 M 58 LN 7 3.2-1.3 pos M SCLC staging 87.7 11.7 6.6 2.9 
 
 
8 11 M 76 LN 7 1.8-0.6 neg N normal 
enlarged 
adrenal gland 75.3 3.1 3.2 0.6 
 
9 12 M 75 LN 7 1.8-0.3 neg N normal staging 95.8 1.8 26.6 3.3 
 13 M 75 LN 4L 3.6-4 pos M SCLC staging 69.0 9.2 3.1 1.0 
 
10 14 F 67 LN 7 1.5-0.1 neg N normal 
primary tumor 
punc 69.9 4.5 8.7 0.8 
 
     15 F 67 LN 4L 1.8-0.2 neg N normal 
primary tumor 
punc 94.4 3.2 16.1 3.2 
 
 
Table 1. Characteristics of patients and lymph nodes included in the current pilot study.  Nodes 
were classified (Class) as normal (N) or metastatic (M).  Note both normal and metastatic nodes 
were measured in patients 3 and 9.  Patient 2 had a positive cytology for a lymph node located at 
location LN 5/6 that was not measured by SF reflectance spectroscopy.   
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Figure 1. Setup used for optical measurements made during EUS-FNA staging of mediastinal 
lymph nodes.  This measurement utilizes a single optical fiber to deliver white light to the lymph 
tissue in vivo and collect light remitted light to the spectrophotometer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Single fiber reflectance spectra and model fit as measured in metastatic (top) and normal 
(bottom) lymph nodes within the same patient (patient 9, nodes 12 and 13 in Table 1).  Spectra are 
shifted on horizontal axis for clarity (arbitrary units).  These spectra show differences in both the 
oxygenation (StO2) and volume fraction ( ρ ) of blood.   
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Summary 
 
Background: Although several studies indicate an additional value of PET in small 
cell lung cancer (SCLC), the acceptance is limited. 
Objectives: To study the additional value of soft tissue lesions detection with PET 
scanning in patients with SCLC. 
Methods: A retrospective analysis of patients, in whom both CT and PET scanning 
were available in the staging work-up. 
Results: Sixty-three patients were included. Thirty-six patients were staged as 
limited disease by CT scan, 2 patients were up staged to extended disease after 
PET scanning due soft tissue lesions. CT scan staged 27 patients as extended 
disease. In 3 patients, soft tissue lesions found with CT scanning were not 
confirmed with PET scanning, resulting in a down staging. These findings resulted 
in 5 of 63 patients (7.9%) a change in staging (95% CI 1.2-14.6). 
Conclusion: PET scanning seems a valuable tool in detecting soft tissue lesions 
and improving staging of SCLC. 
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Introduction 
Lung cancer is the second most common cancer in men and women, and is the 
leading cause of cancer related death. In industrialized countries the mortality rate 
in lung cancer exceeds breast, colorectal and prostate cancer combined [1].  Small 
cell lung carcinoma (SCLC) accounts for approximately 15% of all the diagnosed 
lung cancers [2,3]. SCLC is an aggressive type of lung cancer, associated with 
high metastases rate. Common metastasis localisations are brains, bones and soft 
tissue lesions like liver and adrenal glands. Although TNM staging is 
recommended in SCLC [4], for therapeutic reasons it is divided into limited and 
extended disease. Limited disease is characterized by tumors confined to one 
hemithorax. Involvement of supraclavicular nodes is acceptable if they encompass 
the same radiation portal as the primary tumor. All other disease is classified as 
extensive disease [5]. Standard treatment is (concomitant) chemotherapy and 
radiotherapy in patients with a limited stage SCLC, and chemotherapy alone in 
patients with extended SCLC. Sixty to seventy percent of all diagnosed SCLC is 
extended disease. 
Current diagnostic staging modalities include contrast enhanced computerized 
tomography (CT) scan of chest and upper abdomen, bone scanning and CT scan 
or magnetic resonance imaging (MRI) of the brain [6,7]. Bone scanning and CT or 
MRI of the brain is able to detect bone and brain metastasis respectively. For 
detection of soft tissue metastasis we have to rely on the CT scan. Although 
positron emission tomography (PET) imaging improves accuracy of staging in 
patients with NSCLC [8], the role in staging patients with SCLC is less well defined 
[7]. Several studies [9-16] have suggested that PET scanning, added to the 
conventional staging, is more sensitive for detection of extended disease, but PET 
scanning is not a standard procedure yet.  
In the Netherlands CT and PET scanning are regularly performed in patients 
without clinical signs of metastatic disease in case of a suspicion of lung cancer to 
reduce time to diagnosis and treatment. Therefore we were able to collect data of 
patients in whom the diagnosis SCLC was established. As no standard bone-
scanning was performed our data are only related to the detection of soft tissue 
lesions. Our aim was, to study the additional value of PET scanning in detection of 
soft tissue lesions in patients with SCLC. 
 
 
Patients and Methods 
We retrospectively analysed data of patients who were diagnosed with SCLC in 
the Amphia General Hospital in Breda, the Netherlands between June 2004 and 
January 2008. As the present study is a retrospective observational study, the 
national law in our country requires neither institutional review board approval nor 
informed consent. Patients who received a CT scan and a PET scan were seen 
because of an abnormal chest radiograph. When no signs of extensive metastatic 
disease were apparent, CT scan, bronchoscopy and PET scan were planned 
during the first consultancy to reduce time to diagnosis. 
All patients who received CT scan and PET scan in the work up to diagnose SCLC 
were reviewed. Cytology or histology was obligatory in all patients. CT scanning 
was performed between 2004 and august 2007 by a General Electric type: 
CTI, spiral scan, single slice, 7 mm coupes. Hereafter CT scanning was carried 
out by a Siemens Definition 64 slice dual source, 5 mm slice coupes. Contrast 
enhanced imagines were made of the thorax and the upper abdomen, including 
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the adrenals and the liver. CT head was performed in patients without evidence of 
extended disease or in case of clinical suspicion. PET scanning in the Amphia 
General Hospital started in 2004. Whole body PET-imaging was performed 60 
minutes after intravenous injection of 300 – 500 MBq 2-deoxy-2-[18]fluoro-D-
glucose, after a six hour fasting period, on a Siemens Ecat Exact PET-scanner. 
None of the patients was diabetic or had a fasting blood glucose level above 
120mg/dL. Scans were performed using a two-dimensional acquisition mode from 
the thigh to the skull base with seven bed positions. Each bed position was 
composed of 1 min of transmission scanning and 5 min of emission scanning. Due 
to low sensitivity the cerebrum was not analysed by PET scanning.   
 
 
Results 
In total 63 patients diagnosed with SCLC underwent CT and PET scanning in a 
primary work up between June 2004 and January 2008. Male female ratio was 
1.6. Average age at diagnosis was 67 years. After CT thorax/abdomen and CT 
cerebrum, limited stage was diagnosed in 36 patients (57 %), extended stage was 
diagnosed in 27 patients (43 %) (Figure 1). Average time interval between CT 
scan and PET was 8 days (range -6 to 36 days). Follow up was at least 1 year and 
results were based on the response assessed by CT. 
PET down staged three patients. Lesions found with CT scanning were not 
confirmed with PET scanning. All lesions (2 adrenal glands and 1 liver lesion) were 
soft tissue lesions. Follow up CT scan showed unchangeable lesions after 
chemotherapy. 
PET scanning was responsible for up staging in 2 patients due to detection of 
extrathoracic soft tissue lesions (cervical region and liver metastases). Follow up 
by PET and CT scans showed regression after chemotherapy.  
In total 5 patients (7.9 %) of 63 patients (95% CI 1.2 – 14.6) had a stage shift due 
to soft tissue lesions that were not detected or wrongly interpreted by CT scan 
(table 1). PET scanning showed in 20 patients (31.7%) additional bone lesions. 
One patient, staged as limited by CT scan, showed additional liver lesions but also 
skeletal lesions. This scan was not considered as an additional value scan, 
because the bone lesions could also be detected by a bone scan. Two patients 
who were limited staged, also after PET scanning, showed brain metastasis after 
CT cerebrum. 
No differences in the results between the 2 different CT–scanning modalities could 
be established. 
 
 
Discussion 
In this retrospective study PET scanning lead to a stage shift in 7.9% due to soft 
tissue lesions. In 3 patients who were diagnosed as extended disease with CT-
scanning, PET scanning was negative in these CT-suspicious lesions. In 2 
patients additional soft tissue lesions were found with PET scanning, resulting in 
an upstaging. 
Accurate staging is essential in the work-up of SCLC. Chemotherapy in 
combination with thoracic irradiation can promote long-term survival in patients 
with limited stage, but risk of complications such as irradiation pneumonitis or 
oesophagitis is high. This causes worsening of patient’s quality of life or even 
treatment related death. 
Role of PET scanning in small cell lung cancer with emphasis on soft tissue lesions 
 
105 
False positive lesions detected on CT-scan cause under treatment and poor 
survival. It is considered unacceptable to stage patients solely based on imaging, 
and pathological conformation is required. In clinical practice this conformation is 
not always possible for several reasons like, a lesion which is not assessable for 
puncture. PET is a non-invasive tool, which can be helpful in these patients. A 
negative PET excludes metastases and could avoid 3 unnecessary punctures in 
this study.  
Positive PET is not proving for metastases and pathological confirmation is 
required. In this study, similarly to Niho et al. [15], we did not confirm pathologically 
the additional metastases detected by PET scanning. The lesions were followed 
up during treatment and this was considered as proof of origin. Follow up was at 
least one year and results were based on the response assessed by CT.  
Skeletal lesions are frequently missed by CT (sensitivity is reported 30%) [17]. In 
our series additional bone lesions were established in 20 patients (31.7%). Bone 
scintigraphy was not performed regularly added to PET. Because PET scanning 
was done upfront, no confirmatory bone scanning was performed, which can be 
considered controversial. Formally in case of limited disease SCLC a bone 
scanning should have been performed. The reason that no standard bone 
scintigraphy was performed is based on studies suggesting that PET might even 
be superior to bone scan in detecting bone metastasis [10,14,17]. Fischer et al. 
reported in patients with SCLC sensitivity of detection of bone metastasis by bone 
scintigraphy and PET scanning of 75% and 80% respectively [17]. Another study 
revealed 84% identical metastatic bone lesion detection between bone scan and 
PET scan [14]. Our results about a stage shifting after PET in patients with bone 
metastases cannot be related to general practice. 
The total stage shift is lower compared to Fischer et al. [17] and Brink et al. [10]  
who concluded that PET induced a stage shifting in 17% and 12% of respectively 
29 and 120 patients diagnosed with SCLC. In these studies unexpected bone 
metastasis detected by PET scanning were also included in the analysis. 
By doing a retrospective analysis a selection bias is present. To reduce time to 
diagnosis and treatment CT scan and PET scan were planned simultaneously on 
the first consultancy. Especially in those patients without clear signs of metastatic 
disease, PET scanning was done. This explains the higher than expected number 
of limited disease compared to extended disease and also the number of limited 
metastatic sides.  
Because the study is retrospective some drawbacks, like missing histopathology 
on positive soft tissue lesions and selection bias, are inevitable. Despite these 
drawbacks we believe that our results are of value for the general oncologist, and 
do add to the present literature in the way that we do present a rather large series. 
It is known that PET/CT is superior to PET imaging alone [18]. PET/CT decreases 
imaging time per patient and significantly reduces the number of equivocal PET 
interpretations. PET/CT also has the ability to improve accuracy of PET image 
interpretation [19]. In this study, PET scanning was performed by a stand alone 
PET scan.   
As PET has a low sensitivity for the detection of brain metastases, this was not 
analysed in this study. Patients underwent routinely a CT cerebrum to analyse the 
presence of cerebral lesions. Two patients who were limited staged also after PET 
scanning, showed brain metastasis after CT cerebrum. 
 
 
Chapter 7 
 
106 
Conclusion 
In conclusion, although our study has some limitations, PET adds to the accuracy 
of diagnosing soft tissue metastases in patients with SCLC disease resulting stage 
shift in 5 of 63 patients (7.9%) (95% CI 1.2-14.6). For bone metastases its value 
above CT-scanning is apparent but, as no comparison with bone scanning was 
performed, no conclusions on the comparison of PET with bone scanning can be 
drawn. Additional prospective investigations about optimal staging procedures in 
small cell lung cancer should be performed. 
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10 patients up staged 
to extended disease 
 26 patients stayed 
limited disease 
36 patients limited 
disease  
27 patients extended 
disease 
PET scan PET scan 
63 patients CT scan 
3 patients down staged 
to limited disease 
Due to PET positive 
soft tissue lesions: 2 
Due to PET positive 
skeletal lesions: 8 
Due to PET negative 
soft tissue lesions:3  
Due to PET negative 
skeletal lesions: 0 
24 patients stayed 
extended 
Additional soft 
tissue lesions: 5 
Additional skeletal 
lesions: 12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: Five patients with stage shift after PET scanning due to soft tissue lesions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: sixty-three patients diagnosed with SCLC staged by CT and PET scan 
 
patient CT scan result PET scan result Comment Follow up
1 Extended 
stage
Limited stage Adrenal masses 
on CT, negative 
on PET
Follow up CT 
showed still 
enlarged left 
adrenal
2 Extended 
stage
Limited stage Liver lesion 
detected by CT 
scan, PET is 
negative
Follow up CT 
showed still 
enlarged liver 
lesion
3 Extended 
stage
Limited stage Adrenal masses 
on CT, negative 
on PET
Follow up CT 
showed still 
enlarged left 
adrenal
4 Limited stage Extended stage Positive lesions in 
the liver by PET 
scan
Follow up PET 
showed 
disappearing of 
liver lesions
5 Limited stage Extended stage PET detected 
additional a lesion 
in the cervical 
region
Follow up CT 
scan showed 
lesion regression
Stage shift after PET scanning due to soft tissue lesions
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Abstract 
 
Introduction: Small cell lung cancer (SCLC) is an aggressive tumor with poor 
prognosis. Positron Emission Tomography (PET) scanning is widely used in 
staging of Non-Small Cell Lung Cancer (NSCLC), and the SUVmax value seems 
to have a prognostic value. Limited results of the prognostic and predictive value 
of SUVmax in SCLC are available. 
Methods: a prospective study in 75 chemonaive patients diagnosed with SCLC 
and a PET scan before treatment was performed. SUVmax values of the primary 
tumor were related to the overall survival (OS) and the progression free survival 
(PFS). To investigate SUVmax, patients were divided in a low SUVmax and high 
SUVmax group according to the median SUVmax level. Separate analyses in 
limited and extended disease patients were performed.  
Results: Significant lower SUVmax values of the primary tumor were observed in 
patients with limited disease (LD) compared to extended disease (ED). By 
subdividing the total population in low and high SUVmax groups, no significant 
differences in OS and PFS were observed. Analysis in the patients staged as LD, 
between high and low SUVmax revealed no significant in OS and PFS. In patients 
stages as ED, significant differences in OS and PFS survival were found between 
the low and high SUVmax groups. The patients with ED and a high SUVmax value 
had a significant better OS (p-value 0.005) and a longer PFS (0.002). 
Conclusion: In patients with SCLC, SUVmax was higher in ED compared to LD. 
A high SUVmax is a predictive factor for prolonged PFS and OS, probably due to a 
beneficial effect of chemotherapy which we ascribe to the increased 
chemosensitivity in these patients. In LD SUVmax was found not to be a predictive 
factor. 
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Introduction 
Small cell lung carcinoma (SCLC) accounts for approximately 15% of all the 
diagnosed lung cancers [1, 2]. This type of lung cancer associated with a high 
mitotic rate and widespread metastatic disease. Consequently, prognosis in these 
patients is poor and overall survival rates are disappointingly low.  
Historically, SCLC is classified as either limited disease (LD) or extended disease 
(ED) which is mainly based on treatment options. Limited disease is defined as a 
disease confined to the ipsilateral hemithorax which can be encompassed by a 
single radiotherapy port [3], ED is defined as a disease beyond that ipsilateral 
thorax. Recently it has been advocated to stage SCLC similar to non-small cell 
lung cancer (NSCLC) according to the TNM system [4]. 
A number of parameters have been studied as possible prognostic factors in 
SCLC [5, 6], but none are reliable enough to base treatment decision on. In 
patients with NSCLC it was shown that metabolic activity on 18FDG PET is 
correlated with survival [7-11]. There is a suggestion that 18FDG PET scanning 
also carries prognostic information in SCLC [12]. In recent years fluorine-18 
fluorodeoxyglucose positron emission tomography 18FDG-PET improved staging 
of SCLC [3, 13-17]. Because SCLC staging with PET scanning is acceptable, this 
study could be performed. In the present prospective study we evaluate whether 
the standardized uptake value (SUVmax) of 18FDG of the primary tumor during 
PET scanning has prognostic and predictive value in both limited and extended 
disease with respect to progression free survival (PFS) and overall survival (OS). 
 
 
Patients and methods 
This is a single center prospective study. All patients with a histological or 
cytological confirmation of the diagnosis SCLC and a PET scan before treatment 
were included between January 2007 and December 2008. The decision to 
perform a PET scan was made by the treating physician. Staging was performed 
by standard procedure: patients history and physical examination, chest X-ray, CT 
Thorax and abdomen, CT brain and when clinical indicated bone scintigraphy. 
This study was approved by the institutional board of the Amphia Hospital (Breda, 
The Netherlands). Patients were divided into LD and ED. LD was defined as 
disease restricted to one hemi thorax with regional lymph node metastases. These 
included hilar and mediastinal ipsilateral and contralateral as well as ipsi- and 
contralateral supraclavicular lymph nodes. All patients with sites of disease 
beyond the definition of limited disease were defined as ED. Ipsilateral pleural 
effusion was considered as ED. The PET scan caused stage shifting in 6 patients 
(8%). Two patients were down staged by virtue of FDG negative enlarged adrenal 
glands and 4 patients were upstaged. 
 
PET imaging 
Whole body PET-imaging was performed 60 minutes after intravenous injection of 
300 – 500 MBq 18-F-fluorodeoxyglucose (FDG), after a six hour fasting period, on 
a Siemens Ecat Exact PET-scanner. None of the patients was diabetic or had a 
fasting blood glucose level above 120 mg/dL. Scans were performed using a two-
dimensional acquisition mode from the thigh to the skull base with seven bed 
positions. Each bed position was composed of 1 min of transmission scanning and 
5 min of emission scanning.  
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The images were reviewed on an interactive video display provided by the 
equipment manufacturer. The maximum standard uptake values (SUVmax) was 
quantitative used to determine FDG PET activity. SUVmax was defined as 
maximum tumor concentration of FDG divided by the injected dose, corrected for 
the body weight of the patients: (SUVmax = maximum activity 
concentration/[injected dose/body weight]). The SUVmax was the peak SUV in 
one pixel with the highest counts within the region of interest. The region of 
interest was only the primary tumor. With use of the CT scan, primary tumor was 
localized by the radiologist. To obtain the SUVmax, all images were analyzed by a 
single investigator. 
 
Treatment and follow up 
Treatment modalities were evaluated for each patient (table 1). First line 
chemotherapy was either Cisplatin-Etoposide or Carboplatin-Etoposide. 
Prophylactic cranial irradiation was administered to all patients without radiological 
signs of brain metastases. The primary end point was OS, defined as the date of 
the PET scan to the date of death. Patients who were still alive were censored.  
Progression-free survival (PFS) was defined as the date of the PET scan to date 
of first progression or date of death in patients without progression. Progression 
was defined as local regional and/or new metastasis observed by Chest X-ray, CT 
or PET scan. All patients were evaluated at a 6-8 weeks interval. 
 
Data analysis 
Differences in SUVmax between LD and ED were evaluated using a two-tailed 
Student’s t test. Patients were subdivided into high and low SUVmax according to 
median SUVmax level. Multivariate linear regression models were used to adjust 
the association between high and low SUVmax and PFS or OS for age, gender 
and performance score by the Eastern Cooperative Oncology Group (ECOG). 
Survival time was estimated by the Kaplan-Meier method and the survival 
difference between groups was assessed by the log-rank test. The SPSS 15.0 for 
Windows software was used for statistical analyses. A p-value of <0.05 was 
considered significant. 
 
 
Results 
Patient characteristics 
75 patients, 29 women and 46 men, with a mean age of 66 years (range 49 - 81) 
were included. Follow up was at least 12 months. Of these patients 19 were still 
alive at the end of the study, 52 died and 4 were lost to follow up. Among these 
patients LD was staged in 35 patients and ED in 40 patients. Of the patients 
diagnosed with LD, 26 were treated with chemotherapy and radiotherapy 
(concurrent or sequential), 4 underwent surgery, 3 did not receive any treatment 
and 2 were lost of follow up. These last 5 patients were excluded from PFS 
analysis. The patients with LD received a median of 4 chemotherapy cycles (range 
1-4). Median OS of the patients with LD was 12.1 months.  
Of the patients with ED 28 received chemotherapy, 10 had no treatment and 2 
were lost to follow up. These last 12 patients were excluded from PFS analysis. 
Median number of chemotherapy cycles in this group was 3.0 (range 1-5). Median 
OS of the treated ED patients was 7.0 months.  
 
SUVmax during PET scanning in small cell lung cancer; similar information as in non-small cell 
lung cancer? 
115 
SUVmax and follow up 
SUVmax of the primary tumor was higher in the patients with ED compared to LD 
(figure 1) (p-value= 0.02). Median SUVmax value of the primary tumor of the study 
population was 11.3.   
OS difference was not present between high and low SUVmax in all treated 
patients (p= 0.342) Also no OS differences between high and low SUVmax was 
present in all non-treated patients (p= 0.291). In the patients with LD no significant 
differences in PFS and OS were established between high and low SUVmax (table 
2). When taking into account only the patients who were treated with chemo 
radiotherapy (n=26) again no differences could be established. 
In patients with ED, OS was significant longer in the group of patients with the high 
SUVmax (p-value 0.005). In the patients with ED and no treatment, there was no 
difference in OS between a high or low SUVmax (p=0.196), but this group (n=10) 
is too small to draw conclusions. Distribution of SUVmax between ED with or 
without treatment was equally. When looking at patients with ED and treated with 
chemotherapy both OS (p = 0.008) and PFS (p= 0.002) were favorable for the high 
SUVmax population (figure 3 and 4).  
 
 
Discussion 
We studied whether SUVmax had prognostic or predictive value in patients 
diagnosed with SCLC. SUVmax value were higher in ED compared to LD. Results 
showed no prognostic or predictive value of SUVmax in the total group. In LD no 
relation between SUVmax and OS or PFS were found. In ED, SUVmax did have a 
predictive value. Patients with ED who were treated with chemotherapy and a high 
SUVmax had both prolonged OS and PFS.  
The general assumption is that the high mitotic activity of SCLC results in a high 
SUVmax and we hypothesized that a higher SUVmax be associated with more 
advanced disease. This hypothesis was supported by our result as the SUVmax in 
ED was significantly higher compared to SUVmax in LD. 
Surprisingly we found a higher SUVmax in patients with ED to be associated with 
a better survival after chemotherapy. Our data in patients with ED are in contrast 
to published data in NSCLC, where a low SUV is in general associated with a 
better prognosis [9, 10, 18-20]. Most of these studies are performed in early stage 
NSCLC and therefore cannot necessarily be extrapolated to more advanced 
stages of the disease. 
OS and PFS in our group are, as in general in SCLC, shorter then NSCLC. We 
found that the high metabolic rate in ED is associated with a better response to 
chemotherapy which increases survival. This is supported by Lee et al. [21] where 
85 chemonaive patients with advanced NSCLC were included. Response rate and 
survival were analyzed according to SUVmax.  Response rate on chemotherapy in 
the patients with NSCLC was better in patients with high SUVmax values. They 
concluded similar to our results that tumors with a high SUVmax were a predictive 
factor for OS. We found differences in OS and PFS which we hypothesize to be 
related to the tumor behavior of SCLC. SCLC is a tumor with high mitotic activity 
and for this reason high SUV values are present. As in general a high mitotic rate 
makes a tumor chemosensitive, chemotherapy response is often very good. 
Based on our findings we suggest that chemotherapy response will be higher in 
patients with high SUVmax. This will cause a delay in disease recurrence and 
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increase overall survival in the high SUVmax group compared to the lower 
SUVmax group.  
In a study by Lee et al [12], the role of 18FDG-PET as prognostic factor in SCLC 
was studied, in a population of 76 patients. They investigated the relationship 
between OS and the SUVmax of the primary lesion. Just like us, they did not 
found significant results for the complete group. Whether they looked at the 
subpopulations LD and ED and the SUVmax of the primary lesion is not 
mentioned in their paper. They determined an alternative SUV parameter, the 
meanSUVmax, which showed in the complete group a better PFS and OS in 
patients with a low meanSUVmax compared to the patients with a high 
meanSUVmax. Patients with LD and a high meanSUVmax showed significant 
shorter OS and PFS compared to LD with low meanSUVmax. Identical results 
were observed in ED.  
For a number of reasons the usage of SUVmax was preferred above a 
meanSUVmax in our study. Firstly, metabolic activity of lung cancer lesions varies 
depending on the sites of metastatic disease. SUVmax value is higher in bone 
metastasis compared to lymph node metastasis or solid organ metastasis [22]. 
This will have major influences on a meanSUVmax value. Secondly, in most 
published data, SUVmax of the primary tumor is used as the discriminated factor 
and consequently our results can be compared to these studies. 
The number of patients with ED compared to LD is lower then expected in the 
general population of patients with SCLC. All patients were referred for PET 
scanning during the diagnostic work, but the decision for PET scanning was made 
by the patients treating physician. In patients with clear evidence of metastatic no 
PET scan will be performed, which may be the reason of the lower number of 
included patients with ED. 
PET scan is nowadays a standard tool in the work-up of NSCLC. It is not 
implemented in the standard work-up of SCLC yet. But, as the number of studies 
on the better accuracy of staging with PET scanning is increasing, we think that 
PET scanning will be standard of care in the near future. Based on the results of 
the present study analysis of metabolic activity may give additional predictive 
value. In conclusion, we investigated the value of SUVmax in patients with SCLC. 
Patients diagnosed with an ED and a high SUVmax value had a better PFS and 
OS compared to ED and a low SUVmax. Further research has to be done on this 
subject to establish whether SUVmax can contribute in treatment options. For 
instance, it could be studied whether SUVmax might be a parameter in the 
decision of the number of chemotherapy cycles for SCLC patients staged with ED. 
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number of patients
Total 75
Gender
    Male 46
    Female 29
Age
     <65 36
     >65 39
ECOG
      0-2 62
      >2 13
Stage
     LD 35
     ED 40
Treatment LD
      Surgery 4
      Chemo/RT concurrent 19
      Chemo/RT sequential 7
      None 3
      Unknown     2
Treatment ED
    Chemotherapy 28
    None 10
    Unknown 2
Status LD
     Alive 13
     Death 20
     Lost of follow up 2
Status ED
     Alive 6
     Death 32
     Lost of follow up 2
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1: patients’ characteristics 
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Mean OS
± SD (days) 
LD total 9.65 1.18 - 18.40 368 ± 172 275 ± 145
     Low SUVmax 6.60 1.18 - 11.05  359 ± 171 281 ± 146
      High SUVmax 12.88 11.47 - 18.40 379 ± 178 0.427 268 ± 150 0.78
 ED total 11.88 4.75 - 25.99 189 ± 154 144 ± 83
     Low SUVmax 8.16 4.75 - 10.94 114 ± 110 99 ± 61
     High SUVmax 14.35 11.47 - 25.99 239 ± 161 0.005 181 ± 81 0.002
ED with treatment 11.20 4.75 - 19.41 210 ± 144 144 ± 83
     Low SUVmax 7.82 4.75 - 10.11 138 ± 116 99 ± 61
     High SUVmax 13.70 11.47 - 19.41 264 ± 142 0.008 181 ± 81 0.002
P-valueSUVmax 
mean
SUVmax 
range
P-value Mean PFS ± 
SD (days)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Results of SUVmax between LD low and high SUVmax and ED low and high SUVmax. 
Low and high SUVmax was determined by the median SUVmax of 11.3. P-values adjusted for age, 
gender and ECOG 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Error bars (95 CI of mean) significance differences in SUVmax between LD (0)  
and ED (1) (p-value 0.02) 
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Figure 2: Overall survival curve, all patients diagnosed ED. Lower curve (0) are the patients with a 
low SUVmax, upper curve (1) are the patients with a high SUVmax (p= 0.005) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Overall survival curve, all patients diagnosed ED and treated with chemotherapy. Lower 
curve (0) are the patients with a low SUVmax, upper curve (1) are the patients with a high SUVmax 
(p= 0.008) 
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Figure 4: Progression-free survival curve, all patients diagnosed ED and treated with 
chemotherapy. Lower curve (0) are the patients with a low SUVmax, upper curve (1) are the 
patients with a high SUVmax (p= 0.002) 
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Detection of premalignant lesions using optical imaging techniques 
Lung cancer is a disease with a poor prognosis [1]. Due to nonspecific symptoms, 
most of the patients are diagnosed with advanced stage of the disease when 
therapeutic options are limited. Detection at an earlier stage or in a premalignant 
phase seems to increase survival [2]. 
At the moment, premalignant lesions are too small for detection by radiological or 
nuclear modalities. Only by endoscopic techniques detection is possible. In the 
last 20 years improved imaging techniques with better diagnostic yield for 
premalignant lesions have been developed [3, 4], but all these techniques have 
limitations. Detection of premalignant lesions can be divided into wide-field optic 
imaging and point (spectroscopic) techniques. In chapter 2 these different imaging 
techniques are discussed. Current knowledge of biological changes in 
premalignant lesions and the advantages and limitations of each imaging 
technique are described. To improve detection of premalignant lesions it is 
necessary to combine several techniques. We suggest that the highest potential 
value will be the combination of autofluorescence bronchoscopy with optical 
coherence tomography (OCT) and differential path length spectroscopy (DPS). 
Autofluorescence bronchoscopy is the wide-field optical technique which has been 
studied most. This technique is able to detect potential suspect lesions, however 
specificity is limited. OCT and DPS are able to confirm the positive lesions seen by 
autofluorescence bronchoscopy. OCT is able to measure epithelial thickness. DPS 
is able to inform about local physiology, such as peripheral microvascular 
saturation, vessel diameter and blood volume fraction. DPS and OCT can be used 
separately during bronchoscopy but for clinical practice, to save time, a new probe 
should be developed. This probe should contain two 440 µm fibers incorporated in 
the protective tube of the OCT probe. These fibers have to be positioned in such a 
way that they will not disturb the OCT imaging. This is possible when the DPS 
fibers are located on the tip of the probe and pass by the OCT prism at the back 
site. In this way OCT view will not be hampered by the DPS fibers and DPS 
measurements could be performed by placing the tip of the probe on the area of 
interest.  
 
Differential path-length spectroscopy (DPS) during bronchoscopy in lung 
cancer 
DPS is a spectroscopic technique, which is able to provide information about local 
physiology of investigated areas [5, 6]. A DPS measuring system that could 
determine spectroscopy during bronchoscopy in vivo was developed. 
Microvascular saturation of peripheral tumor tissue is one of the physiology 
parameters that can be obtained. It is not only interesting to use DPS technique in 
premalignant lesions but also in malignant lesions. Hypoxia is well known in solid 
tumors and Bard et al. detected a decrease of peripheral microvascular saturation 
in bronchial carcinomas compared to normal tissue with DPS measurements 
during bronchoscopy [6].  
In chapter 3 the relation between hypoxia related protein hypoxia-inducible-factor 
1a (HIF1a) and microvascular saturation, measured by DPS, is discussed. 
Elevated HIF1a expression is caused by hypoxia [7-10]. The aim of the study was 
to correlate the spectroscopic measurements with an independent parameter for 
hypoxia. DPS measurements were performed in normal and malignant lung 
lesions. A positive correlation between HIF1a expression and low microvascular 
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saturation of bronchial tissue measured by DPS was found. This study showed 
that non-invasive DPS measurements do represent tissue physiology. 
Historically, lung cancer is subdivided in Non-Small Cell Lung Cancer (NSCLC) 
and Small Cell Lung Cancer (SCLC) due to its prognosis and treatment options 
[11, 12]. Because of recent new therapeutic modalities, there is more emphasis to 
subdivide lung cancer into the four major subclassifications: adenocarcinomas 
(ADC), squamous cell carcinomas (SCC), large cell carcinomas (LCC) and SCLC 
[13-15]. In chapter 4 the hypoxia related parameter microvascular saturation was 
studied in subtypes of lung cancer. It was shown that there was no difference in 
saturation between NSCLC and SCLC, although significant differences between 
the histological subclassifications were observed. ADC and SCC had a higher 
microvascular saturation compared to LCC and SCLC. The lower microvascular 
saturation of LCC and SCLC suggests a poorer vascular network due to the type 
of tumor. No differences in survival were observed between high and low 
saturated carcinomas. Therefore, peripheral microvascular saturation, measured 
with DPS, is not a prognostic parameter. More research has to be performed to 
determine the impact of differences in peripheral microvascular saturation of 
histological tumor subtypes. When reflectance spectroscopy would only be 
performed in stage I or II tumors, microvascular saturation might be a prognostic 
marker. As these tumors are seldom seen with bronchscopy, these measurements 
have to be performed during computer tomography guided transthoracic puncture. 
Additionally, reflectance spectroscopy might also help the physician locating the 
peripheral tumor during the procedure.  
 
Spectroscopy during endoscopic ultrasound-guided fine needle aspiration 
Staging is important in lung cancer for prognosis and treatment [16]. Nowadays, 
new techniques like endoscopic ultrasound-guided fine needle aspiration (EUS-
FNA), have been incorporated in the work-up of staging [17]. This EUS-FNA 
technique is less invasive compared to mediastinoscopy. Although 
mediastinoscopy is still gold standard, EUS-FNA is an interesting alternative 
considering it is less expensive, and less likely to induce complications than 
surgical staging procedures [18-22]. EUS-FNA shows a high diagnostic yield, 
however the false negative rate is a problem [19-22]. It is known that the 
vasculature changes in malignant lymph nodes. Aberrant vessels, displacement of 
vessels or even avascular areas of the central lymph nodes have been observed 
[23, 24]. In vivo determination of lymph node physiology might improve the 
diagnostic value. In chapter 5 the incorporation of single fiber reflectance 
spectroscopy during EUS-FNA is described. To obtain spectroscopic data from 
lymph nodes a probe had to be made which was small enough to be guided 
through the EUS needle. For this study setup, a new mathematical model had to 
be developed to analyze the reflectance spectroscopy data. Additionally absorber 
bilirubin was added in order to gain a better fit. Also information about 
manipulation within the lymph nodes was gained. Pressure of the probe on the 
tissue or a release afterwards resulted in differences in lymph node physiology. In 
this chapter the technical feasibility of single fiber reflectance spectroscopy is 
described. 
In chapter 6 the first clinical pilot study on single fiber reflectance spectroscopy 
during EUS-FNA is reported. Single fiber reflectance spectroscopy was 
successfully performed without complications. The technique was performed in 
small normal lymph nodes and enlarged malignant lymph nodes. Differences in 
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microvascular saturation and blood volume fractions were observed between 
malignant and normal lymph nodes. Both microvascular saturation and blood 
volume fraction were lower in malignant lymph nodes. This pilot study showed that 
single fiber reflectance spectroscopy measurement is sensitive for vascular 
changes in lymph nodes.   
 
Functional imaging in Small Cell Lung Cancer (SCLC) 
Apart from optical imaging techniques, functional imaging modalities have the 
ability to provide information about tumor microenvironment as well. Reflectance 
spectroscopy informs about the microenvironment of a small area, often not more 
than 160 µm deep. Functional imaging techniques provide information about a 
larger area and furthermore provide complementary information (e.g. glycolysis). 
PET scanning has become a standard procedure in staging and tumor work up in 
NSCLC [25]. In contrast to NSCLC, in SCLC bone scintigraphy is advised instead 
of PET scanning, because of the high incidence of bone metastases. Although 
several studies showed a higher sensitivity in the detection of bone metastasis 
with PET scanning compared to bone scintigraphy [26-28], PET scanning has not 
yet been accepted as a standard tool in the staging procedure of patients with 
SCLC. 
In chapter 7 the role of PET scanning in the detection of soft tissue metastases in 
patients with SCLC has been studied. In this study PET scanning was able to find 
additional soft tissue lesions that had not been found by the regular work up. The 
PET scan was also able to refute suspect lesions detected by the CT scan. PET 
scan was responsible for stage shift in 7.9%.  The parameter maximal standard 
uptake value (SUVmax) has been studied extensively in patients with NSCLC [29-
33]. Most of these studies demonstrated a low SUVmax value is correlated with a 
better prognosis. In chapter 8 the SUVmax value in patients diagnosed with SCLC 
has been studied. In this chapter it becomes clear that SUVmax seems to be a 
predictive marker. Patients diagnosed with extended disease (ED) and a high 
SUVmax value had longer overall survival and longer progression free survival 
after chemotherapy treatment. Metabolic activity was higher in ED patients 
compared to LD.  
DPS measurements obtained during bronchoscopy showed low microvascular 
saturation in the SCLC group. Also mediastinal lymph nodes of patients with SCLC 
had low microvascular saturation. Therefore, it can be hypothesized that PET 
scanning with a 18F fluoromisonidazole tracer will be of value in patients 
diagnosed with SCLC. This tracer, which is sensitive for hypoxia, should be able to 
distinguish between a reactive lymph node and a malignant lymph node.  
 
Future perspective 
As described in the thesis, a study using with OCT and DPS has been proposed to 
improve the detection of premalignant lesions. This will show the additive value of 
the combination of the two point imaging techniques. At first, this study should be 
performed in patients with a high risk for lung cancer. This group includes patients 
after curative resections of NSCLC, patients with head and neck tumors, or with a 
smoking history. Preferably a randomized trial with two groups should be 
performed: single autofluorescence bronchoscopy versus autofluorescence 
bronchoscopy combined with OCT and DPS. Surveillance autofluorescence 
bronchoscopy with or without point measurement techniques should be performed 
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every 3-6 months for patients with severe dysplasia or CIS [34], otherwise every 
12 month for screening.  
There are still many questions about microenvironmental changes of tumors 
during treatment of tumors. DPS measurements may be of value for in vivo 
analysis of the microenvironment. Studies in which tumor vascularization is 
examined by DPS before and after treatment with angiogenesis inhibitors or 
vascular disrupting agents may provide information about the influence of tumor 
vascularization on the choice of treatment. Also questions about how angiogenesis 
inhibitors or vascular disrupting agents change the tumor vascularization after 
treatment might be answered. 
In this thesis, the first study on single fiber reflectance spectroscopy during EUS-
FNA was described. Whether single fiber reflectance spectroscopy can reduce the 
false negative rate of malignancy should be the subject of further studies. All 
spectroscopically measured lymph nodes which are negative on cytology by EUS-
FNA, should be confirmed by mediastinoscopy to establish the value of reflectance 
spectroscopy in this group. By using spectroscopy during EUS-FNA more basic 
questions about malignant transformation of lymph nodes may be answered as 
well. 
PET scanning in patients with SCLC is not incorporated in the staging standards 
but most studies showed additional value of this imaging technique [27, 28, 35-39]. 
In this thesis it was found to add to staging. Further research should compare 
standard staging (CT scan and bone-scintigraphy) with PET-CT scan staging. In 
addition we have found indications that SUV values obtained during PET scan 
may be predictive. Further studies in larger populations have to be performed to 
confirm our findings. Whether SUV may add to the choice and duration of 
treatments should be studied next.  
 
General conclusion 
Optical imaging plays an important role in the detection of premalignant lesions. 
One of these optical imaging techniques is DPS. This technique is able to inform 
about the microvascular saturation, which is correlated with HIF1a expression. 
DPS can be used during bronchoscopy to provide information about microvascular 
saturation in the different histological subclassifications of lung cancer.  
Furthermore it was possible to obtain useful spectra of mediastinal lymph nodes 
during EUS-FNA. These measurements can be done during an EUS-FNA 
procedure without complications. Differences in spectra and physiological 
parameters between normal and malignant lymph nodes were seen. 
At last the value of PET scanning in SCLC was examined. We showed that PET 
scanning provided additional information in the staging of patients diagnosed with 
SCLC. With PET scanning SUVmax value can be obtained, which seemed to be a 
predictive marker. Patients with ED SCLC and a high SUVmax had better overall 
survival and progression free survival after chemotherapy treatment. 
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Opsporing van premaligne laesies door optische beeldvorming  
De longkanker is een ziekte met een slechte prognose [1]. Vanwege niet-
specifieke symptomen worden de meeste patiënten gediagnosticeerd wanneer er 
sprake is van een vergevorderd stadium van de ziekte. Op dat moment zijn er 
beperkte therapeutische opties beschikbaar. Detectie van de ziekte in een eerder 
stadium of in de premaligne fase lijkt tot langere overleving te leiden [2].  
Op dit ogenblik zijn de premaligne laesies te klein voor opsporing met 
radiologische of nucleaire beeldvorming. Slechts met endoscopische technieken is 
opsporing mogelijk. De laatste 20 jaar zijn de beeldvormingstechnieken verbeterd 
wat geresulteerd heeft in betere detectie van premaligne afwijkingen [3, 4], 
desondanks hebben alle ontwikkelde technieken beperkingen. Detectie van 
premaligne laesies kan worden verdeeld in “wide-field optic imaging” en in “point 
(spectroscopic) techniques”. In hoofdstuk 2 worden de verschillende 
beeldvormingstechnieken besproken. De huidige kennis van de biologische 
veranderingen in premaligne laesies wordt beschreven. Vervolgens wordt 
aangegeven wat de voordelen en beperkingen zijn van elke techniek. Op dit 
moment is het nog noodzakelijk om verscheidene technieken te combineren om 
opsporing van premaligne laesies te verbeteren. Wij zijn van mening dat de 
combinatie van technieken met de grootste potentie is: autofluorescentie 
bronchoscopie gecombineerd met optical coherence tomography (OCT) en 
differential path length spectroscopy (DPS). Autofluorescentie bronchoscopie is de 
meest bestudeerde “wide-field optic imaging” techniek. Deze techniek kan 
verdachte laesies detecteren, nochtans is de specificiteit beperkt. OCT en DPS 
kunnen worden gebruikt om te bevestigen of laesies, gedetecteerd met 
autofluorescentie bronchoscopie, daadwerkelijk premaligne zijn. Middels OCT 
wordt de epitheliale dikte gemeten, DPS geeft informatie over de lokale fysiologie, 
zoals perifere microvasculaire saturatie, vaatdiameter en bloedvolume fractie. 
DPS en OCT kunnen los van elkaar worden gebruikt tijdens een bronchoscopie. 
Om tijdwinst te boeken zou een nieuwe probe gemaakt kunnen worden waarbij 
twee 440 µm fibers worden ingebracht in de bescherm huls van een OCT probe. 
Deze twee fibers dienen zo te worden bevestigd dat deze niet het beeld van OCT 
belemmeren. Dit is mogelijk wanneer de fibers worden bevestigd op het uiteinde 
van de probe en langs de achterzijde van de OCT-prisma lopen. Hiermee wordt 
het beeld dat middels OCT wordt verkregen niet verstoord door de twee DPS 
fibers. Vervolgens kunnen DPS data worden verkregen door het plaatsen van de 
probe op de gewenste locatie. 
 
Differential path length spectroscopie (DPS) gemeten tijdens bronchoscopie 
bij patiënten met longkanker 
DPS is een spectroscopische techniek die informatie verschaft over de lokale 
fysiologie van het onderzochte weefsel [5, 6]. Een DPS metingssysteem is 
ontwikkeld dat de spectra in vivo kan bepalen tijdens bronchoscopie. Eén van de 
verkregen fysiologische parameters is de microvasculaire saturatie van perifeer 
tumorweefsel. DPS is een techniek die niet alleen waardevol is bij premaligne 
laesies maar ook in maligne laesies. Het is bekend dat er sprake is van hypoxie in 
maligniteiten, Bard et al. toonden aan dat de perifere microvasculaire saturatie, 
gemeten met DPS tijdens bronchoscopie, lager is in bronchiale carcinomen in 
vergelijking met normaal weefsel [6].  
In hoofdstuk 3 word de relatie van hypoxie gerelateerd eiwit hypoxia-inducible-
factor 1a (HIF1a) en de microvasculaire saturatie, gemeten met DPS, besproken. 
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Verhoogde HIF1a expressie wordt veroorzaakt door hypoxie [7-10]. Het doel van 
de studie was om reflectie spectroscopische metingen te correleren met een 
onafhankelijke parameter voor hypoxie. DPS metingen zijn gedaan in normaal 
longweefsel en in maligne longweefsel. Er bleek een correlatie te zijn tussen 
HIF1a expressie en lage microvasculaire saturatie van het bronchiale weefsel 
gemeten met DPS. Deze studie toonde aan dat deze niet-invasieve techniek 
informatie geeft over weefselfysiologie.  
In het verleden werd longkanker op basis van prognose en behandelingsopties 
onderverdeeld in niet-kleincellig longkanker (NSCLC) en kleincellig longkanker 
(SCLC) [11, 12]. Tegenwoordig zijn er meer therapeutische mogelijkheden en is 
het beter om longkanker onder te verdelen in vier subklassen op basis van 
histologie: adenocarcinoom (ADC), plaveiselcel carcinoom (SCC), onge-
differentieerde grootcellig longcarcinoom (LCC) en SCLC [13-15]. In hoofdstuk 4 
is de hypoxie parameter microvasculaire saturatie in de verschillende 
histologische subklassen van longkanker bestudeerd. Er bleek geen verschil te 
zijn in microvasculaire saturatie van NSCLC en SCLC. Wel werden er significante 
verschillen waargenomen tussen de histologische subklassen. ADC en SCC 
hadden een hogere microvasculaire saturatie in vergelijking met LCC en SCLC. 
De verlaagde microvasculaire saturatie in LCC en SCLC kan veroorzaakt zijn door 
een slecht vasculair netwerk dat samenhangt met de histologie van de tumor. Er 
werd geen verschil in overleving aangetoond tussen carcinomen met een hoge en 
lage saturatie. Perifere microvasculaire saturatie, gemeten met DPS, is daarom 
geen voorspellende parameter. Meer onderzoek is nodig om aan te tonen wat de 
klinische toepasbaarheid is van de verschillen in perifere microvasculaire saturatie 
tussen de histologische subtypen. Wanneer reflectie spectroscopie verricht zou 
worden in stadium I en II tumoren zou microvasculaire saturatie mogelijk een 
prognostisch marker zijn. Deze metingen zouden CT geleid trans-thoracaal 
kunnen worden verricht. De reflectie spectra zouden dan ook de onderzoeker 
kunnen helpen bij het bepalen van de positie van de perifere tumor. 
 
Spectroscopie tijdens endoscopische echografie met dunne naald aspiratie 
Stadiëring is van belang bij de diagnose longkanker, zowel voor prognose als de 
keus van behandeling [16]. Tegenwoordig zijn nieuwe technieken opgenomen in 
de stadiërings onderzoeken, zoals endoscopische echografie met dunne naald 
aspiratie (EUS-FNA) [17]. EUS-FNA is minder invasief dan de gouden standaard 
mediastinoscopie. EUS-FNA is een interessant alternatief omdat het goedkoper is 
en waarschijnlijk minder kans op complicaties geeft [18-21]. EUS-FNA heeft een 
hoge diagnostische opbrengst, hoewel de fout negatieve bevindingen nog een 
probleem zijn [19-22]. Het is bekend dat vaatopbouw verandert in maligne 
lymfeklieren. Afwijkende vaten, foutieve aanleg van vaten of zelfs avasculaire 
gebieden van centrale lymfeklieren zijn waargenomen [23, 24]. In vivo 
determinatie van lymfeklier fysiologie zou de diagnostische waarde kunnen 
verbeteren. In hoofdstuk 5 wordt de integratie van single fiber reflectie 
spectroscopie tijdens EUS-FNA beschreven. Om spectroscopische gegevens van 
lymfeklieren te verkrijgen moest een probe worden gemaakt, die klein genoeg was 
om door de EUS naald te worden geleid. Voor deze studieopstelling moest een 
nieuw wiskundig model worden ontwikkeld om de reflectie spectroscopische data 
te analyseren. Licht absorberend bilirubine werd toegevoegd om beter passende 
spectra te verkrijgen. Ook werd bestudeerd wat manipulatie binnen in de 
lymfeklieren voor effect heeft op de spectra. De druk van de probe op het weefsel 
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of het terug trekken van de probe na meting resulteerde in verschillen in lymfeklier 
fysiologie. In dit hoofdstuk is technische haalbaarheid aan van single fiber reflectie 
spectroscopie beschreven.  
In hoofdstuk 6 wordt de eerste klinische studie van single fiber reflectie 
spectroscopie tijdens EUS-FNA beschreven. De single fiber reflectie 
spectroscopie werd met succes uitgevoerd zonder complicaties. De techniek werd 
uitgevoerd in kleine normale lymfeklieren en vergrootte maligne lymfeklieren. Er 
werden verschillen waargenomen in microvasculaire saturatie en bloedvolume 
fracties tussen maligne en normale lymfeklieren. Zowel microvasculaire saturatie 
als bloedvolume fractie was lager in maligne lymfeklieren. Dit onderzoek toonde 
aan dat single fiber reflectie spectroscopie gevoelig is voor vasculaire 
veranderingen in lymfeklieren.  
 
Functionele beeldvorming in kleincellig long carcinoom (SCLC)  
Naast optische technieken kunnen ook functionele beeldvormingstechnieken 
informatie verschaffen over het tumormilieu. Reflectie spectroscopie geeft alleen 
informatie over een klein gebied, vaak niet dieper dan 160 µm. Functionele 
technieken kunnen informatie geven over grotere gebieden en daarbij aanvullende 
informatie geven (bijvoorbeeld over glycolyse). Het verrichten van een PET scan is 
onderdeel van de standaardprocedure in de stadiëring van NSCLC [25]. In SCLC 
wordt de skeletscan, in plaats van de PET scan, geadviseerd vanwege de hoge 
incidentie van botmetastasen. Hoewel verschillende studies een hogere 
gevoeligheid in het opsporen van botmetastasen toonden bij gebruik van een PET 
scan in vergelijking met een skeletscan [26-28], is het verrichten van een PET 
scan nog niet ingevoerd als standaard beeldvorming bij de stadiërings procedure 
van patiënten met SCLC. In hoofdstuk 7 is de rol van de PET scan in de 
opsporing van weke delen metastasen in patiënten met SCLC bestudeerd. In deze 
studie kon de PET scan weke delen laesies aantonen die niet bij de standaard 
beeldvormende technieken werden gevonden. De PET scan kon ook verdachte 
laesies weerleggen die door de CT scan als maligne beschouwd waren. Door de 
PET scan was er in 7,9% van de patiënten een verandering van stadium.  
De parameter maximale gestandaardiseerde opname waarde (SUVmax) is 
uitvoerig bestudeerd in patiënten met NSCLC [29-33]. Het merendeel van deze 
studies toonde aan dat een lage SUVmax waarde gerelateerd is met een betere 
prognose. In hoofdstuk 8 is de SUVmax waarde in patiënten met SCLC 
bestudeerd. SUVmax blijkt een predictieve marker te zijn. Patiënten met 
uitgebreide ziekte en een hoge SUVmax waarde hadden een langere overleving 
en een langere ziekte-vrije overleving wanneer zij behandeld werden met 
chemotherapie. Metabole activiteit was hoger in patiënten met uitgebreide ziekte 
dan patiënten zonder uitgebreide ziekte. 
 
Toekomst perspectief  
Zoals beschreven in dit proefschrift kan de opsporing van premaligne laesies 
worden verbeterd door een studie te starten waarin autofluorescentie 
bronchoscopie gecombineerd wordt met OCT en DPS. Deze studie moet de 
toegevoegde waarde van de combinatie van deze twee “point (spectroscopic) 
techniques” aantonen. Deze studie zou aanvankelijk in hoog risico patiënten met 
longkanker moeten worden uitgevoerd. Deze groep omvat: NSCLC patiënten 
waarbij een curatieve resectie heeft plaatsgevonden, patiënten met hoofd-hals 
tumoren, of patiënten die veel gerookt hebben. Het zou bij voorkeur een 
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gerandomiseerde studie moeten zijn met twee groepen: autofluorescentie 
bronchoscopie versus autofluorescentie bronchoscopie gecombineerd met OCT 
en DPS. Controle autofluorescentie bronchoscopie, met of zonder “point 
(spectroscopic) techniques”, dient in patiënten met ernstige dysplasie of 
carcinoma in situ om de 3-6 maanden uitgevoerd te worden [34]. Bij de overige 
patiënten dient controle autofluorescentie bronchoscopie, met of zonder “point 
(spectroscopic) techniques”, om de 12 maanden plaats te vinden.  
Er is nog veel onduidelijkheid over de veranderingen van het tumor micromilieu 
tijdens behandeling. DPS metingen kunnen van betekenis zijn voor in vivo analyse 
van het tumor micromilieu. DPS metingen, voor en na behandeling met 
angiogeneseremmers of vascular disrupting agents, kunnen informatie geven over 
werking van deze medicatie. Andersom zou onderzocht kunnen worden wat het 
effect is van angiogeneseremmers of vascular disrupting agents op tumor 
vascularisatie.  
In dit proefschrift wordt de eerste studie over single fiber reflectie spectroscopie 
tijdens EUS-FNA beschreven. Of single fiber reflectie spectroscopie het aantal fout 
negatieve bevindingen van EUS-FNA in maligne lymfeklieren kan verlagen moet 
bekeken worden in een volgende studie. Patiënten die lymfeklieren hebben die 
tijdens EUS-FNA meting met reflectie spectroscopie cytologisch negatief blijken te 
zijn, zouden vervolgens een mediastinoscopie moeten ondergaan om de waarde 
van reflectie spectroscopie te bepalen. Door spectroscopie tijdens EUS-FNA te 
gebruiken, kunnen meer onderzoeksvragen over maligne transformatie van 
lymfeklieren worden beantwoord.  
Vooralsnog is een PET scan bij patiënten met SCLC nog niet opgenomen in de 
standaard stadiërings onderzoeken, maar meerdere studies toonden de additieve 
waarde van deze functionele beeldvormende techniek [27, 28, 35-39]. In dit 
proefschrift werd de toegevoegde waarde van de PET scan bij stadiering 
beschreven. Verder onderzoek zou moeten plaatsvinden waarbij de standaard 
stadiërings onderzoeken, bestaande uit CT-scan en skeletscan, vergeleken 
moeten worden met PET-CT-scan. Daarnaast blijkt dat de SUVmax waarden die 
tijdens PET scan worden verkregen een predictieve waarde hebben. Verdere 
studies met een grotere groep patiënten moet worden uitgevoerd om onze 
bevindingen te bevestigen. Of SUVmax waarden kunnen bijdragen aan de keus 
en de duur van behandeling zou moeten worden uitgezocht.  
 
Algemene conclusie 
Optische weergave speelt een belangrijke rol bij de opsporing van premaligne 
laesies. Één van deze optische technieken is DPS. Deze techniek geeft informatie 
over de microvasculaire saturatie en is gerelateerd aan HIF1a expressie. DPS kan 
worden gebruikt tijdens bronchoscopie en kan informatie geven over de 
microvasculaire saturatie in de verschillende histologische subklassen. Daarnaast 
was het mogelijk om spectra van mediastinale lymfeklieren tijdens EUS-FNA te 
verkrijgen. Deze metingen kunnen worden verricht zonder complicaties. Er waren 
verschillen meetbaar in spectra en fysiologische parameters tussen normale en 
maligne lymfeklieren. Tot slot is de waarde van PET scanning in SCLC 
onderzocht. Aangetoond werd dat PET scanning extra informatie geeft wat leidt tot 
beter stadiëren van patiënten met SCLC. Met de PET scan kan een SUVmax 
waarde worden verkregen, dit lijkt een predictieve marker te zijn. SCLC patiënten 
met uitgebreide ziekte en een hoge SUVmax waarde hebben een betere 
overleving en ziekte-vrije overleving na behandeling met chemotherapie.  
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LIST OF ABBREVIATIONS  
 
 
18F-FDG  18F-Fluorodeoxyglucose 
ADC   Adenocarcinoma 
ASD   Angiogenetic squamous dysplasia 
CIS   Carcinoma in situ 
CT   Computer Tomography 
DPS   Differential pathlength spectroscopy 
ED   Extended disease 
EUS-FNA  Endoscopic ultrasound fine needle aspiration 
HIF1a   Hypoxic inducible factor 1 alpha 
LCC   Large cell carcinoma 
LD   Limited disease 
NSCLC  Non small cell lung carcinoma 
OS   Overall survival 
PET   Positron emission tomography 
PFS   Progression free survival 
SCC   Squamous cell carcinoma 
SCLC   Small cell lung carcinoma 
SF   Single fiber 
SUVmax  Maximum standard uptake value 
VEGF   Vascular endothelial growth factor 
 
 
Abbreviations of the used mathematical equations 
DPS (λ)  Reflectance Spectra 
λ    Wavelength [nm] 
λ0    Wavelength at 800 nm [nm] 
µs    Coefficient of light scattering [1/cm] 
µa    Coefficient of light absorption [1/cm] 
µa’    Corrected coefficient of light absorption [1/cm] 
τ    Pathlenght, distance of light traveling trough the tissue [cm] 
a    Mie amplitude 
b    Mie slope 
ρ    Blood volume fraction  
µa
oxyHemo
   Absorption of oxygenated hemoglobin [1/cm of 100% volume 
fraction] 
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µa
Hemo
   Absorption of deoxygenated hemoglobin [1/cm of 100% 
volume fraction] 
µa
other
    Other vascular absorbers [1/Mol] 
µa
hom
    Homogeneously distributed absorber  [1/Mol] 
StO2   Oxygen saturation of the blood [%] 
R   Radius of the blood vessel [cm] 
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